

Contents

1	Affinity LIGANDS	5	Education and Training
1	Analytical Techniques	5	Emerging Technologies
1	Antisense Technology	6	Environmental Issues
1	Aseptic Processing	6	Enzymes
1	Automation	6	European Economic Community
1	Biopreservation	6	Expression Systems
1	Biosensors	6	Facility Design and Construction
1	Biotechnology Basics	6	Filtration
2	Business Issues	6	Financial Strategies
2	Cell Growth and Viability	7	Gene Therapy
2	Cell Harvesting	7	Good Laboratory Practices
2	Chromatography	7	Good Manufacturing Practices
3	Clean-In-Place Systems, Clean rooms	7	Government Policies
3	Computers: Hardware and Software	8	Intellectual Property Rights
3	Contamination Control	8	International Business
4	Contract Services	8	Investigational New Drug Applications
5	Controlled Environments	8	Legal Issues
5	DNA Assay Methods	8	Legislation
5	Documentation	8	Mammalian Cell Culture
5	Downstream Processing	9	Media
5	Drug Discovery		
5	Drug Formulation and Delivery		
		9	Microbial Fermentation
		9	Monoclonal Antibodies
		9	Monoclonal Antibodies
			Recovery
		9	New Drug Applications
		9	Oligonucleotides
		9	Patents
		10	Personnel Issues
		10	Plant Biotechnology
		10	Posttranslational Processing
		10	Process Automation
		10	Process Control/
			Monitoring
		10	Protein Denaturation
		11	Protein Folding
		11	Protein Precipitation
		11	Protein/Polypeptide
			Recovery
		11	QA/QC
		12	Regulatory Issues
		13	Scale-Up Strategies
		13	Separation and Purification
		14	Sera and Serum Substitute
		14	Standard Operating
			Procedures
		14	Statistics
		14	Transgenics
		14	Validation
		15	Viral Inactivation
			Columns
		16	Business Matters
		16	GMP Issues
		16	Inside Washington
		16	Managing Your Career
		17	Outsourcing Outlook
		17	Patent Law You Can Use
		17	Regulatory Affairs
		18	Your Vested Interests
			Departments
		18	Analytical Advances
		18	Guest Editorial
		18	Travel Notes
		18	Viewpoints

BioPharm International*

Article Index (1998–2002)

Affinity Ligands

- Affinity Chromatography is Vital to Protein Research and Development. J.M. Curling, October 2001, pp. 51–52.
- Comparing the Safety of Synthetic and Biological Ligands Used for Purification of Therapeutic Proteins. M. Behizad, J.M. Curling, September 2000, pp. 42–46.
- Customized Ligands Optimize Affinity Chromatography Procedures. L. Larsson, January 2001, pp. 42–44.

Analytical Techniques

- A Guide to Determining Sample Sizes and Outlier Criteria in Analytical Investigations. J.D. Hofer, E.C. Rickard, May 2001, pp. 32–41, 68.
- Advances in Amino Acid Analysis. J.C. Anders, April 2002, pp. 32–39, 67.
- Analytical Standards and Controls. S.S. Kuwahara, April 1998, pp. 57–58.
- Biomolecular Interaction Analysis Mass Spectrometry: A Multiplexed Proteomics Approach. D. Nedelkov, R.W. Nelson, August 2001, pp. 28–33.
- Combining ELISA, RP-HPLC, and SDS-PAGE to Define the Potency of a Complex Biologic. J.R. Zabrecky et al. October 1998, pp. 30–34.
- Designs for Bioassays with Plate Location Effects. B. Schlain et al. November 2001, pp. 40–44.
- Development of an In Situ Spectroscopic Method for Cleaning Validation Using Mid-IR Fiber-Optics. N.K. Mehta et al. May 2002, pp. 36–42, 71.
- Differential Scanning Calorimetry: A Practical Tool for Elucidating Stability of Liquid Biopharmaceuticals. R.L. Remmele Jr., W.R. Gombotz, June 2000, pp. 36–46.
- Employing Near-Infrared Spectroscopic Methods of Analysis for Fermentation Monitoring and Control: Part 1, Method Development. S.A. Arnold et al. November 2002, pp. 26–34.
- High-Throughput Synthesis and DNA Chips. R.J. Molinari, July 1998, pp. 34–36.
- Intentionally Degrading Protein Pharmaceuticals to Validate Stability-Indicating Analytical Methods. J. Yu, November 2000, pp. 46–50.

- Reexamining the “Set It and Forget It” Approach. P. Poulter, September 2002, pp. 14–15, 65.
- Replacing Slab Gel Electrophoresis Methods with Capillary Electrophoresis for Quality Control and Stability Testing. S.H. Bowen, M.A. Schenerman, November 1998, pp. 42–46, 50.
- Spectroscopic Determination of Chelator Content in Antibody–Chelator Conjugates. E. Dadachova, November 2000, pp. 40–44.
- Strategies for Host Cell Protein Analysis. K. Hoffman, May 2000, pp. 38–45.
- Systematic Troubleshooting for LC/MS/MS: Part 1, Sample Preparation and Chromatography. N. Weng, T.D.J. Halls, November 2001, pp. 28–38.
- Systematic Troubleshooting for LC/MS/MS: Part 2, Large-Scale LC/MS/MS and Automation. N. Weng, T.D.J. Halls, January 2002, pp. 22–26, 49.
- Using Molecular Beacons to Quantify Low Levels of Type I Endonuclease Activity. R.J. Strouse et al. April 2000, pp. 40–47.

Antisense Technology

- Nucleic Acid Drug Delivery: Part 1, Delivery Issues Related to Dividing Cells. S. Wu-Pong, D.A. Gewirtz, November 1998, pp. 28–35.
- Nucleic Acid Drug Delivery: Part 2, Delivery to the Brain. S. Wu-Pong, D.A. Gewirtz, January 1999, pp. 32–38.
- Reviewing Antisense Oligonucleotide Therapy: Part 1, Action and Design. S.K. Das, K.J. Miller, October 1999, pp. 42–48.
- Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues. S.K. Das, K.J. Miller, November 1999, pp. 44–51.

Aseptic Processing

- Design and Validation of Isolator Systems for the Manufacturing and Testing of Health Care Products: Highlights from the New PDA Technical Report No. 34. R.E. Madsen, July 2001, pp. 30–32.
- Isolators Revisited: The Current State of Implementation. J.E. Akers Jr. April 2000, pp. 30–33.

Automation

- Reliability Issues in High-Throughput Screening Systems. D.W. Brandt, February 1998, pp. 30–32.

- Software for Biopharmaceutical Companies. C. Scott, February 1999, pp. 22–32.

Biopreservation

- Developing Large-Scale Cryopreservation Systems for Biopharmaceutical Products. R. Wisniewski, June 1998, pp. 50–60.
- Freezing Bulk-Scale Biopharmaceuticals Using Common Techniques — and the Magnitude of Freeze-Concentration. S.D. Webb et al. May 2002, pp. 22–34.
- Large-Scale Cryopreservation of Cells, Cell Components, and Biological Solutions. R. Wisniewski, September 1998, pp. 42–49, 61.
- The Basics of Laboratory-Scale Mammalian Cell Cryopreservation. L. Wolfenbarger, October 1998, pp. 35–39.

Biosensors

- Biomolecular Interaction Analysis Mass Spectrometry: A Multiplexed Proteomics Approach. D. Nedelkov, R.W. Nelson, August 2001, pp. 28–33.
- Comparative Performances of 70 Ion-Exchange Chromatography Sorbents for Purification of Biomolecules. J. Dennis, P. Levison, C. Mumford, April 1998, pp. 44–50.
- Comparing the Safety of Synthetic and Biological Ligands Used for Purification of Therapeutic Proteins. M. Behizad, J.M. Curling, September 2000, pp. 42–46.
- Defining Critical Variables in Well-Characterized Biotechnology Processes. R.J. Seely et al. April 1999, pp. 33–36.

Biotechnology Basics

- A System Developer's Approach to Validation. C.L. Gent, March 2002, pp. 46–50, 72.
- Biopharmaceutical Shipping: Moving at the Speed of Life. J. Johnson, March 2001, pp. 34–36.
- European Editor's Report: An Industry Comes of Age. K. Robinson, November 2002, pp. 20–24.
- From Discovery to Development: Part 1, Erasing the Line Between R&D. C. Scott, D. Wendt, November 1998, pp. 22–26, 53.
- From Discovery to Development: Part 2, Moving Forward. C. Scott, D. Wendt, January 1999, pp. 26–30.

*The Index covers the period from January 1998 through December 2002. The publication was known as *BioPharm* until the November 2002 issue when it became known as *BioPharm International*.

- From R&D to Licensing: What to Do and When to Do it. G. Sofer, January 2001, pp. 18–27.
- Making Better Decisions: Troubleshooting Biopharmaceutical Processes Using Problem Analysis. J.A. Myers, October 2000, pp. 32–35.
- The Evolving Role of Product Characterization During Development. J. Faulkner, June 2000, pp. 26–34.
- The Future and the Biotechnology Industry: New Trends in Pharmaceutical Development. M.D. Dibner, June 2001, pp. 26–30.

Business Issues

- Avoiding the Trademark Pitfalls of a Start-Up Company. R. Richards, August 1999, pp. 26–30.
- BIO Business: Performance, Not Promises. C.B. Feldbaum, June 2001, pp. 20–24.
- Biotech Financial Markets are Hot, but . . . a Maturing Pipeline is the Key Driver of Contract Services for Biotech Companies. J. Miller, L. Perry, February 2001, pp. 22–24.
- Chaos, Speed, and Value Curves. F.N. Eshelman, July 1998, pp. 36–38.
- Client Confidentiality and Intellectual Property: Key Challenges in Outsourcing. M. Renn, K. Hall, C. Younger, November 2000, pp. 52–54.
- Criminal Penalties for Theft of Biological Materials. L. Howard, June 2002, pp. 64–66, 82.
- Enabling Collaboration in the Pharmaceutical Industry. F. Gossieaux, June 2002, pp. 105–106.
- European Editor's Report: An Industry Comes of Age. K. Robinson, November 2002, pp. 20–24.
- Finding Funding in Biotechnology: Keeping the Companies Alive. M.D. Dibner, M. Howell, June 2002, pp. 35–38.
- Implementing the Biological Weapons Convention Protocol in the United States: What it Means to the Biopharmaceutical Industry. L.C. Klotz et al. August 2000, pp. 46–48.
- In Their Own Words: Five Executives on Success in the Industry. C.J. Steffy, June 2001, pp. 52–58.
- Knowledge Management: The Four Pillars of Success. A. Davis, July 2002, pp. 44–46, 58.
- Making Client Relationships Productive: Tips for the Contract Service Organization. R.S. Woodward, July 2000, pp. 44–46.
- Maturing Biomanufacturing Industry Offers Sponsors Clear Choices and Benefits. H.L. Levine, J.C. Miller, May 1999, pp. 62–64.
- Negotiating and Structuring Strategic Alliances. D. Schulman, J. Zammit-Lucia, C. Easley, June 2002, pp. 72–75, 82.
- Patent Law You Can Use: Part 1, Types of Intellectual Property. H.M. Eisenberg, April 1999, pp. 38–39, 43.
- Preparing Your Project Team for Successful Outsourcing. R.S. Woodward, May 1999, pp. 58–60.
- Preventing Discord in Outsourced Clinical Trials. H. Marais, July 2000, pp. 36–38.
- Restrictive Covenants: Protecting Confidential and Proprietary Information. C.A. Amalfe, K.R. Heslin, February 2000, pp. 52–55.
- Science or Project Management: What (and Who) Is More Important in Biotech?, July 2001, pp. 28–29.
- Stem Cells and Xenotransplantation: Ethics, Patents, and Politics — an Industry Roundtable. June 2002, pp. 19–22, 26–34.
- Successful Technology Transfer: Lessons from Experience. C.J. Dale, October 2000, pp. 48–56.
- Surveying the Field: Your Career in the Biopharmaceutical Industry. A. Muir, May 1999, pp. 28–36.
- Surveying the Field: Your Career in the Biopharmaceutical Industry. A. Muir, May 1999, p. 28.
- Targeted Biomarketing: Helping Biotech Businesses Grow. E. DeRitis, June 2002, pp. 48–56.
- The Biotech Century Begins with a Boom — Then a Bust: Good, Bad, Good, Bad . . . What's Next? G.S. Burrill, June 2001, pp. 42–51.
- The Biotech/Pharmaceutical Industry. D.L. Henry, June 1998, pp. B2–B15.
- The Future and the Biotechnology Industry: New Trends in Pharmaceutical Development. M.D. Dibner, June 2001, pp. 26–30.
- The IRS and the Independent Contractor: Knowing the Rules of the Game. A.E. Schultz, July 2001, pp. 24–26, 70.
- The Squeeze in Contract Biomanufacturing. R. Lias, S. Fogerty, July 2001, pp. 18–22.
- Women's Work: Women and Biotech in the 21st Century. L. McLeod, June 2001, pp. 32–41.

Cell Growth and Viability

- Expanding Cell Culture Manufacturing Capabilities. M. Caple, July 1998, p. 38.
- Production-Scale Qualification of a Novel Cell Culture Medium Format. R. Radominski et al., July 2001, pp. 34–39.
- Replacing the Animal Component in Serum: Evaluating Raw Materials for Inclusion in Optimized Hybridoma Media. S.C. Peppers et al. May 2001, pp. 22–30.
- The Basics of Laboratory-Scale Mammalian Cell Cryopreservation. L. Wolfenbarger, October 1998, pp. 35–39.
- Tutorial: Examining the Relationship Between Media and Light. W.H. Siegel, T. Pritchett, January 2000, pp. 65–66.

Cell Harvesting

- Therapeutic Delivery Issues in Gene Therapy: Part 1, Vectors. D.A. Parasrampur, C.A. Hunt, March 1998, pp. 38–45.

Cell Line Characterization

- Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing: Part 1, Considerations for Technology Transfer and Commercial Development. S. Ford, W.E. Tente, October 2001, pp. 10–16.
- Some Methods for Contamination Testing of a Master Cell Bank. M. Aleman et al, June 2000, pp. 48–52.
- Sterility Testing for Master Cell Banks, Working Cell Banks, and Unprocessed Bulk. G. Sofer, C. Phillips, September 2001, pp. 36–38.

Chromatography

- Affinity Chromatography is Vital to Protein Research and Development. J.M. Curling, October 2001, pp. 51–52.
- Comparative Performances of 70 Ion-Exchange Chromatography Sorbents for Purification of Biomolecules. J. Dennis, P. Levison, C. Mumford, April 1998, pp. 44–50.
- Customized Ligands Optimize Affinity Chromatography Procedures. L. Larsson, January 2001, pp. 42–44.
- Determining the Useful Lifetime of Chromatography Resins: Prospective Small-Scale Studies. R.M. O'Leary et al, September 2001, pp. 10–18.
- High-Throughput Biopharmaceutical Drug Development: Meeting the Coming Challenge. R. Nayar, M.C. Manning, February 2002, pp. 20–28.
- Ion-Exchange Displacement Chromatography: Scale-Up and Displacer Clearance for Recombinant Human Brain-Derived Neurotrophic Factor (rHuBDNF). K.A. Barnhouse, W. Trompeter, September 1999, pp. 35–44.
- Minimizing Risks from Chromatography Media: Management of Raw Materials in Biopharmaceutical Production. R.M. Kennedy, L. Gonzales, May 2001, pp. 56–58.
- Multiuse Chromatography System: A Clean-in-Place Validation Case Study. P. A. Garipey, R.S. Moore, G. Sofer, September 1998, pp. 32–36.
- Process Purification of Polypeptides and Proteins by Reversed-Phase Column Chromatography: Misconceptions and Reality. P. Lu et al., September 2001, pp. 28–35.
- Purifying the Sendai Virus in One Step Using Ion-Exchange Chromatography. J. Eveleth, L. Quaranto, January 2000, pp. 40–43.
- Regulatory Aspects of Column Chromatography in Biopharmaceutical Manufacturing:

- U.S. and EU Regulatory Attitudes Toward Change. M. Behizad, D. Baines, May 1998, pp. 72–82.
- Retrovirus and Parvovirus Clearance from an Affinity Column Product Using Adsorptive Depth Filtration. B. Tipton et al., September 2002, pp. 43–50.
- Storing an Ion-Exchange Chromatography Gel in Dilute Alkali During Recycling Improves Cleaning. J. Turton, Z. Moola, April 2002, pp. 24–30.
- Systematic Troubleshooting for LC/MS/MS: Part 1, Sample Preparation and Chromatography. N. Weng, T.D.J. Halls, November 2001, pp. 28–38.
- Systematic Troubleshooting for LC/MS/MS: Part 2, Large-Scale LC/MS/MS and Automation. N. Weng, T.D.J. Halls, January 2002, pp. 22–26, 49.
- Tutorial: Systems Qualification for High-Performance Liquid Chromatography Systems. L. Huber, November 1998, pp. 65–66, 41.
- Tutorial: Validation of HPLC Methods. L. Huber, March 1999, pp. 64–66.
- Validating the Sanitization of Chromatographic Resins: A Sample Case Study. M. Hiraoka-Sutow, C. Broughton, April 2001, pp. 26–30, 52.
- Validation of a Cation Exchange Method to Test for Residual Amounts of a Cleaning and Sanitizing Solution on Pharmaceutical Process Equipment. M.J. Shifflet, M. Shapiro, January 2000, pp. 51–54, 64.
- Validation of Large-Scale Chromatographic Processes: Part 1, Case Study of Neuleze Capture on Macroprep High-S. T.N. Breece, E. Gilkerson, C. Schmelzer, May 2002, pp. 16–20.
- Validation of Large-Scale Chromatographic Processes: Part 2, Results from the Case Study of Neuleze Capture on Macroprep High-S. T.N. Breece, E. Gilkerson, July 2002, pp. 35–42.
- R.S. Moore, G. Sofer, September 1998, pp. 32–36.
- Storing an Ion-Exchange Chromatography Gel in Dilute Alkali During Recycling Improves Cleaning. J. Turton, Z. Moola, April 2002, pp. 24–30.

Computers: Hardware and Software

- 21 CFR Part 11: (Un)Expected Added Value. J.F. Noferi, D.E. Worden, R. Dillon, February 2002, pp. 44–50.
- Bioinformatics Databases — Questions of Copyright. E. Howard, G. Ramsey, November 2002, pp. 46–48, 64.
- Business Benefits of Computer Systems Validation. M.J. Veverka, March 2002, pp. 52–54, 72.
- Implementing 21 CFR Part 11 in Analytical Laboratories: Part 1, Overview and Requirements. L. Huber, November 1999, pp. 28–34.
- Implementing 21 CFR Part 11 in Analytical Laboratories: Part 2, Security Aspects for Systems and Applications. W. Winter, L. Huber, January 2000, pp. 44–50.
- Implementing 21 CFR Part 11 in Analytical Laboratories: Part 3, Ensuring Data Integrity in Electronic Records. W. Winter, L. Huber, March 2000, pp. 45–49.
- Implementing 21 CFR Part 11 in Analytical Laboratories: Part 4, Data Migration and Long-Term Archiving for Ready Retrieval. L. Huber, W. Winter, June 2000, pp. 58–64.
- Implementing 21 CFR Part 11 in Analytical Laboratories: Part 5, The Importance of Instrument Control and Data Acquisition. W. Winter, L. Huber, September 2000, pp. 52–56.
- Information Age Audits. J.F. Noferi, D.E. Worden, E.R. Arling, January 2002, pp. 35–39, 50.
- Qualification of Network Components and Validation of Networked Systems. L. Huber, R. Budiandjo, October 2001, pp. 18–26, 46.
- Simplifying Pharmacologic Analysis with Programmable Scientific Software. J.M. Przechocki, November 2001, pp. 46–48.
- Software for Biopharmaceutical Companies. C. Scott, February 1999, pp. 22–32.
- Software Helps Project Managers Organize Time, Human Resources, and Communications. D. Porubek, February 2000, pp. 36–42.
- Specifications and Manufacturing Change Control: A Prototypic System for Electronic Document Tracking and Management. R. Zeid, March 2002, pp. 34–44.
- Spreadsheets: Let Them Collect Their Own Data! G. Forrest, March 1999, pp. 40–44.
- The Platform Approach to Clinical Data Management. D. Goodermote, August 2001, p. 54.
- Throughput Analysis and Debottlenecking of Biomanufacturing Facilities: A Job for Process Simulators. D. Petrides, A. Koulouris, C. Siletti, August 2002, pp. 28–34, 64.
- Tutorial: Qualification of Legacy Equipment in Quality Control Laboratories. L.E. Little, March 1998, pp. 61–62.
- Validating Computer Systems for Clinical Trials, Part 1: Leveraging Your Supplier's Verification Efforts. G. Benghiat, A. Miller, and P. Bleicher, January 1999, pp. 39–41.
- Validating Computer Systems for Clinical Trials, Part 2: The Supplier Audit. G. Benghiat, A. Miller, and P. Bleicher, March 1999, pp. 51–54.
- Validating Computerized Systems Developed Out of House: Reducing the Time It Takes to Market. J. Gottfried, October 1998, pp. 40–43.
- Viewpoint: Y2K Bug — A Millenium Debacle. K.P. Evans, B. Gibson, July 1998, pp. 14–17, 50.

Contamination Control

- An Introduction to Biohazard Safety Cabinetry. R.F. Lohser, L. XiangQian, April 2001, pp. 42–43.
- Assessment of Risk of Bovine Spongiform Encephalopathy in Pharmaceutical Products, Part 1. PhRMA: BSE Committee, January 1998, pp. 20–31, 56.

Clean-In-Place Systems, Cleanrooms

- Multiuse Chromatography System: A Clean-in-Place Validation Case Study. P. A. Garipey,

- Assessment of Risk of Bovine Spongiform Encephalopathy in Pharmaceutical Products, Part 2: Example Risk Assessment for a Hypothetical Product. PhRMA: BSE Committee, March 1998, pp. 18–30.
- Bioburden Determinations: Most Probable Number or Colony Counting? D.W. Cooper, June 1999, pp. 53–55, 90.
- Blow-Fill-Seal Technology: Design Optimization of a Particulate Control System. J. Price, April 1999, pp. 25–29, 43.
- Design and Validation of Isolator Systems for the Manufacturing and Testing of Health Care Products: Highlights from the New PDA Technical Report No. 34. R.E. Madsen, July 2001, pp. 30–32.
- Detecting and Removing Porcine Viruses to Prevent Contamination of Biopharmaceutical Raw Materials. B.J. Potts, W.J. Kivens, May 2000, pp. 26–31.
- Detection of Microbial Contamination in Cell Cultures Using a Laser Scanning System. A.O. Onadipe, April 2001, pp. 38–40.
- Development of an In Situ Spectroscopic Method for Cleaning Validation Using Mid-IR Fiber-Optics. N.K. Mehta et al., May 2002, pp. 36–42, 71.
- Ensuring Successful Validation: The Logical Steps to Efficient Cleaning Procedures. G. Amer, P. Desmane, March 2001, pp. 26–32.
- Evaluation of Two Bovine Cell Lines as Hosts for Detecting Several Common Bovine Viruses in Fetal Bovine Serum. Z.M. Plavsic, September 2000, pp. 48–51.
- Inactivation of Several Bovine Viruses in Fetal Bovine Serum Using pH Adjustments. Z.M. Plavsic et al., November 2000, pp. 34–38.
- Isolators Revisited: The Current State of Implementation. J.E. Akers Jr. April 2000, pp. 30–33.
- Resistance of Porcine Circovirus to Gamma Irradiation. Z.M. Plavsic, S. Bolin, April 2001, pp. 32–36.
- Some Methods for Contamination Testing of a Master Cell Bank. M. Aleman et al., June 2000, pp. 48–52.
- Sterility Testing for Master Cell Banks, Working Cell Banks, and Unprocessed Bulk. G. Sofer, C. Phillips, September 2001, pp. 36–38.
- Strategies for Host Cell Protein Analysis. K. Hoffman, May 2000, pp. 38–45.
- Tutorial: Exploiting the Poisson Distribution for Bioburden Investigations. D.W. Cooper, April 2000, pp. 65–66.
- Validating the Sanitization of Chromatographic Resins: A Sample Case Study. M. Hiraoka-Sutow, C. Broughton, April 2001, pp. 26–30, 52.
- Validation of a Cation-Exchange Method to Test for Residual Amounts of a Cleaning and Sanitizing Solution on Pharmaceutical Process Equipment. M.J. Shifflet, M. Shapiro, January 2000, pp. 51–54, 64.
- Validation of Quantitative PCR Assays: Addressing Virus Contamination Concerns. A. Lovatt et al., March 2002, pp. 22–32.
- Viral Clearance Strategies for Biopharmaceutical Safety: Part 1, General Considerations. H. Aranha, January 2001, pp. 28–35.
- You Have Failed . . . A Case Study in Warning Letter Remediation. J.F. Noferi et al., November 2002, pp. 35–40, 64.

Contract Services

- Becoming a Good and Valued Client: Dos and Don'ts for a Successful Outsourcing Relationship. R.S. Woodward, June 1998, pp. 44–49.
- BioPharm Outsourcing Survey: Version 1.0. S.A. Montgomery, September 1998, pp. 28–30.
- Biotech Financial Markets are Hot, but . . . a Maturing Pipeline is the Key Driver of Contract Services for Biotech Companies. J. Miller, L. Perry, February 2001, pp. 22–24.
- Client Confidentiality and Intellectual Property: Key Challenges in Outsourcing. M. Renn, K. Hall, C. Younger, November 2000, pp. 52–54.
- Considerations for Selecting a Contract Biomanufacturer. D.M. Rehkop, June 1998, pp. 32–34.
- Facilitating Client Audits: The Contract Laboratory Perspective. B. Carter-Hamm, G. Vinson, July 2002, pp. 12–16.
- Keys to Developing an Effective Outsourcing Strategy. R.S. Woodward, February 2000, pp. 22–26.
- Making Client Relationships Productive: Tips for the Contract Service Organization. R.S. Woodward, July 2000, pp. 44–46.
- Maturing Biomanufacturing Industry Offers Sponsors Clear Choices and Benefits. H.L. Levine, J.C. Miller, May 1999, pp. 62–64.
- Outsourcing Biopharmaceutical Manufacturing Operations. S.H. Messing, June 1998, pp. 28–30.
- Outsourcing Industry Leaders Look Ahead to a Bright Future. L. Perry, February 2001, pp. 30, 48.
- Pharmaceutical Companies Provide Unique Contract Service Capabilities. S. Fox, July 2000, pp. 30–34.
- Planning Ahead for Manufacturing Facility Changes: A Case Study in Outsourcing. M. Katz, January 2001, pp. 46–47, 56.
- Preparing Your Project Team for Successful Outsourcing. R.S. Woodward, May 1999, pp. 58–60.
- Preventing Discard in Outsourced Clinical Trials. H. Marais, July 2000, pp. 36–38.
- Project Management of Small R&D Companies: Part 1, Perspective from a Large CRO. F. Beddia et al., February 2001, pp. 26–28.
- Project Management of Small R&D Companies: Part 2, Perspectives from a Large CRO. F. Beddia et al., March 2001, pp. 38–40.
- The Contract Services Landscape: Results from *BioPharm's* Second Outsourcing Survey. P. L. Cass, July 2001, pp. 40–44.
- The IRS and the Independent Contractor: Knowing the Rules of the Game. A.E. Schultz, July 2001, pp. 24–26, 70.

The Quality Agreement: Compliance Considerations in Selecting a Contract Manufacturer. G. Bobrowicz, February 2001, pp. 14–20, 43.

The Reemergence of the Biopharmaceutical Contract Manufacturing Industry. R.L. McKown, May 1999, pp. 54–57.

The Squeeze in Contract Biomanufacturing. R. Lias, S. Fogerty, July 2001, pp. 18–22.

Validating Computerized Systems Developed Out of House. J. Gottfried, October 1998, pp. 40–43.

Controlled Environments

Blow-Fill-Seal Technology: Design Optimization of a Particulate Control System. J. Price, April 1999, pp. 25–29, 43.

Environmental Control and Monitoring in Bulk Manufacturing Facilities for Biological Products. J. Barta, May 1998, pp. 84–89.

Isolators Revisited: The Current State of Implementation. J.E. Akers Jr. April 2000, pp. 30–33.

Learning from Bioburden Count Distributions. D.W. Cooper, March 1998, pp. 32–37.

Tutorial: Exploiting the Poisson Distribution for Bioburden Investigations. D.W. Cooper, April 2000, pp. 65–66.

Tutorial: The Importance of Time Variables in Temperature Studies. P. A. Hugunin, G. Straub, February 2000, pp. 73–74.

DNA Assay Methods

Documentation: It's Not Just Paper Work. D. Feuerhelm, G.S. Blank, August 2001, pp. 18–21, 64.

Strategies for Host Cell Protein Analysis. K. Hoffman, May 2000, pp. 38–45.

Using Molecular Beacons to Quantify Low Levels of Type I Endonuclease Activity. R.J. Strouse et al., April 2000, pp. 40–47.

Validation of a Chemiluminescent Hybridization Assay for Quantitative Determination of Host Cell DNA in Clarified Conditioned Medium. B. DiPaolo, X. Ji, and K. Venkat, May 1999, pp. 38–48.

Documentation

Documentation: It's Not Just Paper Work. D. Feuerhelm, G.S. Blank, August 2001, pp. 18–21, 64.

Responding to FDA-483's and Warning Letters. D.L. Chesney, A.E. Kelly, October 1998, pp. 26–29.

Specifications and Manufacturing Change Control: A Prototypic System for Electronic Document Tracking and Management. R. Zeid, March 2002, pp. 34–44.

Tutorial: Establishing Calibration Intervals, Traceability, and Documentation. D.M. Evans, J. Erickson, June 1998, pp. 73–74.

Writing Procedures That Contribute to Performance. J.L. Vesper, August 2001, pp. 23–26.

Downstream Processing

Comparing the Safety of Synthetic and Biological Ligands Used for Purification of Therapeutic Proteins. M. Behizad, J.M. Curling, September 2000, pp. 42–46.

Determining the Useful Lifetime of Chromatography Resins: Prospective Small-Scale Studies. R.M. O'Leary et al., September 2001, pp. 10–18.

Throughput Analysis and Debottlenecking of Biomanufacturing Facilities: A Job for Process Simulators. D. Petrides, A. Koulouris, C. Siletti, August 2002, pp. 28–34, 64.

Using Molecular Beacons to Quantify Low Levels of Type I Endonuclease Activity. R.J. Strouse et al., April 2000, pp. 40–47.

Drug Discovery

A Historical Perspective. M.J. Suto, February 1998, pp. 28–30.

Accelerating the Discovery of Drugs. L. Bellon, February 1998, p. 26.

Designs for Bioassays with Plate Location Effects. B. Schlain et al., November 2001, pp. 40–44.

Drug Discovery: Affinity and Beyond. N. Janjic, February 1998, p. 28.

Emergence of Chemistry-Based Drug Discovery Companies. E. Field, February 1998, pp. 27–28.

From Discovery to Development: Part 1, Erasing the Line Between R&D. C. Scott, D. Wendt, November 1998, pp. 22–26, 53.

From Discovery to Development: Part 2, Moving Forward. C. Scott, D. Wendt, January 1999, pp. 28–30.

Microbial Biodiversity Provides New Leads for Drug Discovery. T.J. Bruggeman, July 1998, pp. 30–31.

Drug Formulation and Delivery

A Green Revolution for the Health System. G. Hess, L.P. Vezina, July 1999, pp. 22–23.

Formulation Case Studies: A Tutorial. C. Scott, August 2001, pp. 34–35.

Formulation: In the Public Eye. P.L. Cass, November 2001, p. 61.

Liposomes (a Review): Part 1, Manufacturing Issues. S.S. Chrai, R. Murari, I. Ahmad, November 2001, pp. 10–14.

Liposomes (a Review): Part 2, Drug Delivery Systems. S.S. Chrai, R. Murari, I. Ahmad, January 2002, pp. 40–43, 49.

Nonviral Gene Delivery Systems: Part 1, Physical Stability. T.J. Anchordoquy, June 1999, pp. 42–48.

Nonviral Gene Delivery Systems: Part 2, Physical Characterization. T.J. Anchordoquy, September 1999, pp. 46–51.

Nucleic Acid Drug Delivery: Part 1, Delivery Issues Related to Dividing Cells. S. Wu-Pong, D.A. Gewirtz, November 1998, pp. 28–35.

Nucleic Acid Drug Delivery: Part 2, Delivery to the Brain. S. Wu-Pong, D.A. Gewirtz, January 1999, pp. 32–38.

Protein Stability in Pulmonary Delivery Formulations: A Review. R. Krishnamurthy, March 1999, pp. 34–38.

RNA as a Small-Molecule Drug Target. D.J. Ecker, February 1998, pp. 26–27.

Therapeutic Delivery Issues in Gene Therapy: Part 1, Vectors. D.A. Parasrampur, C.A. Hunt, March 1998, pp. 38–45.

Therapeutic Delivery Issues in Gene Therapy: Part 2, Targeting Approaches. D.A. Parasrampur, C.A. Hunt, May 1998, pp. 58–70.

Education and Training

A Practical Guide to Executing Validation Protocols. G.S. Hodgson, April 1999, pp. 30–32.

Biopharmaceutical Shipping: Moving at the Speed of Life. J. Johnson, March 2001, pp. 34–36.

DO NOT Pass Go, DO NOT Collect 2,000 ECUs: The European Union's Centralized Procedure. A. Bowers, S. Hunter, N. Chew, March 2000, pp. 28–38.

Making Better Decisions: Troubleshooting Biopharmaceutical Processes Using Problem Analysis. J.A. Myers, October 2000, pp. 32–35.

Performance: The Goal of Training or Why Training is Not Always the Answer . . . J.L. Vesper, February 2001, pp. 44–46.

Software Helps Project Managers Organize Time, Human Resources, and Communications. D. Porubek, February 2000, pp. 36–42.

Tutorial: Implementing and Managing Calibration Training. D.M. Evans, J. Erickson, October 1998, pp. 57–58.

Writing Procedures That Contribute to Performance. J.L. Vesper, August 2001, pp. 23–26.

Emerging Technologies

Announcing USP Chapter <1046>, "Cell and Gene Therapy Products". S. Seaver, January 2000, pp. 26–29.

Biomolecular Interaction Analysis Mass Spectrometry: A Multiplexed Proteomics Approach. D. Nedelkov, R.W. Nelson, August 2001, pp. 28–33.

Cell and Tissue Therapies: Working with Complex, Mutable, Living Entities. N. Chew, April 2001, pp. 20–24, 66.

- Clinical Programs in Cutting-Edge Technologies: A Guide for Beginning the Development of Novel Therapies. M. Wade, May 1998, pp. 52–56.
- Corn Seed Production of Therapeutic Proteins Moves Forward: One Company's Experience. J. Baez, D. Russell, J. Craig, August 2000, pp. 50–54.
- Differential Scanning Calorimetry: A Practical Tool for Elucidating Stability of Liquid Biopharmaceuticals. R.L. Remmele Jr., W.R. Gombotz, June 2000, pp. 36–46.
- Freezing Bulk-Scale Biopharmaceuticals Using Common Techniques — and the Magnitude of Freeze-Concentration. S.D. Webb et al., May 2002, pp. 22–34.
- High-Throughput Biopharmaceutical Drug Development: Meeting the Coming Challenge. R. Nayar, M.C. Manning, February 2002, pp. 20–28.
- Inactivating Adventitious Viruses While Preserving Biological Activity: Treating Fetal Bovine Serum with Pulsed Ultraviolet Light. M. Sawyer et al., December 2002, 35–40.
- Production of Recombinant Collagen for Biomedical Devices. F. Ruggiero, H. Chanut, A. Fichard, May 2000, pp. 32–37.
- Regulatory Requirements for Somatic Cell Therapy Products: Safety Concerns and Practical Solutions. M.S. Lao, March 2000, pp. 50–55.
- The Future and the Biotechnology Industry: New Trends in Pharmaceutical Development. M.D. Dibner, June 2001, pp. 26–30.
- The Immunogenicity of Therapeutic Proteins. F. Adair, D. Ozanne, February 2002, pp. 30–36.
- The Importance of Freezing on Lyophilization Cycle Development. T.W. Patapoff, D.E. Overcashier, March 2002, pp. 16–21, 72.
- The Industrial Production Costs of Recombinant Therapeutic Proteins Expressed in Transgenic Corn. D. Mison, J. Curling, May 2000, pp. 48–54.
- The Platform Approach to Clinical Data Management. D. Goodermote, August 2001, pp. 54.
- Therapeutic Delivery Issues in Gene Therapy: Part 2, Targeting Approaches. D.A. Parashuram, C.A. Hunt, May 1998, pp. 58–70.
- Transgenic Protein Production: Part 3, Nuclear Transfer Technology. P. Rohricht, D. Ayares, November 1999, pp. 56–60.

Environmental Issues

- Environmental Control and Monitoring in Bulk Manufacturing Facilities for Biological Products. J. Barta, May 1998, pp. 84–89.
- Isolators Revisited: The Current State of Implementation. J.E. Akers Jr., April 2000, pp. 30–33.

Enzymes

- Detecting PEG-rHu MGDF in Rhesus Monkey Serum: An Enzyme-Linked Immunosorbent Assay. D. Chen et al., April 2000, pp. 48–50.
- Meeting the Challenges of Enzyme Assay Validation. U. Patel, July 2000, pp. 48–52.

European Economic Community

- DO NOT Pass Go, DO NOT Collect 2,000 ECUs: The European Union's Centralized Procedure. A. Bowers, S. Hunter, N. Chew, March 2000, pp. 28–38.
- Travel Notes: Snapshots of the Biopharmaceutical Industry in Baden-Württemberg. S.A. Montgomery, May 1998, pp. 22–23.
- Viewpoint: BioRegioN – Using a Virtual Enterprise to Foster a Regional Biotech Industry. U. Jensen, May 1998, pp. 20–21.

European Union (EU)

- European Editor's Report: An Industry Comes of Age. K. Robinson, November 2002, pp. 20–24.
- Regulatory Aspects of Column Chromatography in Biopharmaceutical Manufacturing: U.S. and EU Regulatory Attitudes Toward Change. M. Behizad, D. Baines, May 1998, pp. 72–82.

Expression Systems

- Cancer Gene Therapy Using Plasmid DNA: Pharmacokinetics and Safety Evaluation of an IL-2 Plasmid DNA Expression Vector in Rodents and Nonhuman Primates. S.E. Parker et al., April 1999, pp. 18–24.
- Homologous Recombination in CHO Cells. M. Reff, July 1998, pp. 33–34.
- Optimizing Recombinant Microbial Fermentation Processes: An Integrated Approach. M. Cserjan-Puschmann et al., July 2002, pp. 26–34.
- Pichia pastoris*: A Eukaryotic System for the Large-Scale Production of Biopharmaceuticals. C. Dale, A. Allen, S. Fogerty, November 1999, pp. 36–42.
- Production of Recombinant Collagen for Biomedical Devices. F. Ruggiero, H. Chanut, A. Fichard, May 2000, pp. 32–37.
- Transgenic Protein Production: The Technology and Major Players. P. Rohricht, March 1999, pp. 46–49.

Facility Design and Construction

- Biotech Facilities for the Future. L.J. Stillman, October 1999, pp. 16–18.
- CGMP Pharmaceutical Scale-Up: Part 1, Design. C. Pepper, M. Patel, H. Hartounian, September 1999, pp. 26–34.
- CGMP Pharmaceutical Scale-Up: Part 2, Contractors and the Request for Proposal. C. Pepper, M. Patel, H. Hartounian, October 1999, pp. 36–40, 55.

- CGMP Pharmaceutical Scale-Up: Part 3, Automation. M. Patel, C. Pepper, H. Hartounian, November 1999, pp. 52–54.
- CGMP Pharmaceutical Scale-Up: Part 4, Installation, Commissioning, Development. C. Pepper, M. Patel, H. Hartounian, February 2000, pp. 28–34.
- Facility Qualification Studies. C. DeSain, C.V. Sutton, January 1998, pp. 38–41.
- Isolators Revisited: The Current State of Implementation. J.E. Akers Jr. April 2000, pp. 30–33.
- Successful Technology Transfer: Lessons from Experience. C.J. Dale, October 2000, pp. 48–56.
- The Biotech Century Begins with a Boom - Then a Bust: Good, Bad, Good, Bad... What's Next? G.S. Burrill, June 2001, pp. 42–51.
- The Integration of Design, Construction, and Validation: Solving a Validation Challenge. J.N. Odum, November 1998, pp. 36–41.
- The Reemergence of the Biopharmaceutical Contract Manufacturing Industry. R.L. McKown, May 1999, pp. 54–57.
- Throughput Analysis and Debottlenecking of Biomanufacturing Facilities: A Job for Process Simulators. D. Petrides, A. Koulouris, August 2002, pp. 28–34, 64.

Filtration

- Retrovirus and Parvovirus Clearance from an Affinity Column Product Using Adsorptive Depth Filtration. B. Tipton et al., September 2002, pp. 43–50.
- Viral Clearance Strategies for Biopharmaceutical Safety: Part 1, General Considerations. H. Aranha, January 2001, pp. 28–35.
- Viral Clearance Strategies for Biopharmaceutical Safety: Part 2, Filtration for Viral Clearance. H. Aranha, February 2001, pp. 32–43.

Financial Strategies

- Biotech Financial Markets are Hot, but . . . a Maturing Pipeline is the Key Driver of Contract Services for Biotech Companies. J. Miller, L. Perry, February 2001, pp. 22–24.
- Finding Funding in Biotechnology: Keeping the Companies Alive. M.D. Dibner, M. Howell, June 2002, pp. 35–38.
- In Their Own Words: Five Executives on Success in the Industry. C.J. Steffy, June 2001, pp. 52–58.
- Negotiating and Structuring Strategic Alliances. D. Schulman, J. Zammit-Lucia, E. Easley, June 2002, pp. 72–75, 82.
- Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Bar. T. Brody, February 2002, pp. 38–42.

- Targeted Biomarketing: Helping Biotech Businesses Grow. E. DeRitis, June 2002, pp. 48–56.
- The IRS and the Independent Contractor: Knowing the Rules of the Game. A.E. Schultz, July 2001, pp. 24–26, 70.
- Unlocking the Value of R&D: Managing the Risks. D. Pass, M. Postle, June 2002, pp. 67–71

Gene Therapy

- Announcing USP Chapter <1046>, "Cell and Gene Therapy Products." S. Seaver, January 2000, pp. 26–29.
- Cancer Gene Therapy Using Plasmid DNA: Pharmacokinetics and Safety Evaluation of an IL-2 Plasmid DNA Expression Vector in Rodents and Nonhuman Primates. S.E. Parker et al., April 1999, pp. 18–24.
- Nonviral Gene Delivery Systems: Part 1, Physical Stability. T.J. Anchordoquy, June 1999, pp. 42–48.
- Nonviral Gene Delivery Systems: Part 2, Physical Characterization. T.J. Anchordoquy, September 1999, pp. 46–51.
- Nucleic Acid Drug Delivery: Part 1, Delivery Issues Related to Dividing Cells. S. Wu-Pong, D.A. Gewirtz, November 1998, pp. 28–35.
- Nucleic Acid Drug Delivery: Part 2, Delivery to the Brain. S. Wu-Pong, D.A. Gewirtz, January 1999, pp. 32–38.
- Sequencing by Hybridization. B. D'Elia, P. Hensler, July 1998, p. 30.
- The Future and the Biotechnology Industry: New Trends in Pharmaceutical Development. M.D. Dibner, June 2001, pp. 26–30.
- Therapeutic Delivery Issues in Gene Therapy: Part 1, Vectors. D.A. Parasrampur, C.A. Hunt, March 1998, pp. 38–45.
- Therapeutic Delivery Issues in Gene Therapy: Part 2, Targeting Approaches. D.A. Parasrampur, C.A. Hunt, May 1998, pp. 58–70.

Good Laboratory Practices

- Cell Bank Validation: Comparing Points to Consider and ICH Guidelines. M.S. Lao, January 1999, pp. 48–51.
- An Introduction to Biohazard Safety Cabinetry. R.F. Lohser, L. XiangQian, April 2001, pp. 42–43.
- Analytical Standards and Controls. S.S. Kuwahara, April 1998, pp. 57–58.
- Ensuring Laboratory Compliance. R.H. Johnson, August 1998, pp. 30–32.
- Implementing 21 CFR Part 11 in Analytical Laboratories: Part 1, Overview and Requirements. L. Huber, November 1999, pp. 28–34.
- Implementing 21 CFR Part 11 in Analytical Laboratories: Part 2, Security Aspects for Systems and Applications. W. Winter, L. Huber, January 2000, pp. 44–50.

- Implementing 21 CFR Part 11 in Analytical Laboratories: Part 4, Data Migration and Long-Term Archiving for Ready Retrieval. L. Huber, W. Winter, June 2000, pp. 58–64.
- Reexamining the "Set It and Forget It" Approach. P. Poulter, September 2002, pp. 14–15, 65.
- Statistics for Laboratory Method Comparison Studies. R.T. Magari, January 2002, pp. 28–32.
- Tutorial: Qualification of Quality Control Laboratory Equipment. T.J. Pritchett, January 1998, pp. 57–58.

Good Manufacturing Practices

- A Brief History of the GMPs: The Power of Storytelling. B.K. Immel, August 2000, pp. 26–36, 61.
- A Practical Approach to Investigating GMP Failures. J.F. Huxsoll, August 1999, pp. 39–42.
- Assessment of Risk of Bovine Spongiform Encephalopathy in Pharmaceutical Products: Part 2, Example Risk Assessed for a Hypothetical Product. PhRMA BSE Committee, March 1998, pp. 18–30.
- Beyond QSIT. J.F. Noferi, E.R. Arling, D.E. Worden, April 2002, pp. 40–44, 67.
- Creating Effective Biopharmaceutical QA/QC Organizations: Your People are the Key. E.R. Arling, R. Dillon, J.F. Noferi, June 2002, pp. 40–46.
- Defining Your GMP Training Program with a Training Procedure. J.L. Vesper, November 2000, pp. 28–32.
- Development of an In Situ Spectroscopic Method for Cleaning Validation Using Mid-IR Fiber-Optics. N.K. Mehta et al., May 2002, pp. 36–42, 71.
- Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing: Part 1, Considerations for Technology Transfer and Commercial Development. S. Ford, W.E. Tente, October 2001, pp. 10–16.
- Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing: Part 2, A Case Study. S. Ford, W.E. Tente, November 2001, pp. 16–26.
- Ensuring Successful Validation: The Logical Steps to Efficient Cleaning Procedures. G. Amer, P. Desmane, March 2001, pp. 26–32.
- GMP Compliance from a Production Manager's Point of View. M. Pemberton, August 1998, pp. 34–37.
- GMP, Compliance, and Regulatory Resources on the Worldwide Web: An Update. C. Scott, P. L. Cass, October 2000, pp. 58–62.
- GMP, Compliance, and Regulatory Resources Shine on the Worldwide Web. C. Scott, August 1999, pp. 46–48.
- Keys to Quality Systems for Handling Investigations: Investigating, Documenting, and Resolving Problems. M.L. Balboni, August 2001, pp. 12–17, 63.
- One Product, One Process, One Set of Specifications: A Proven Quality Paradigm for the Safety and Efficacy of Biologic Drugs. T. Copmann et al., March 2001, pp. 14–24.
- Performance: The Goal of Training or Why Training is Not Always the Answer J.L. Vesper, February 2001, pp. 44–46.
- Responding to FDA-483's and Warning Letters. D.L. Chesney, A.E. Kelly, October 1998, pp. 26–29.
- Specifications and Manufacturing Change Control: A Prototypic System for Electronic Document Tracking and Management. R. Zeid, March 2002, pp. 34–44.
- Stepwise Implementation of CGMPs: A "GSP" Approach. L.E. Little, September 1998, pp. 37–41.
- Survival Guide to FDA Inspections: Part 1, To Prepare or Not to Prepare, There is No Question. M. Lavian, P. W. Allen, August 2002, pp. 20–26, 49.
- Survival Guide to FDA Inspections: Part 2, Conducting the Audit — Ready or Not, Here They Come. M. Lavian, P. W. Allen, October 2002, pp. 30–35.
- Survival Guide to FDA Inspections: Part 3, Responding to Observations. M. Lavian, P. W. Allen, November 2002, pp. 42–44.
- Survival: It's All About Compliance. C. Scott, L. McLeod, October 2000, pp. 65–67.
- The Compliance Costs of Hasty Process Development. G. Bobrowicz, August 1999, pp. 35–38.
- The Quality Agreement: Compliance Considerations in Selecting a Contract Manufacturer. G. Bobrowicz, February 2001, pp. 14–20, 43.
- Using a Model and Tools to Standardize the Preparation for a Preapproval Inspection. B.W. Unger, February 2002, pp. 14–18, 71.
- Validating a Refrigerator-Freezer. P.A. Cloud, November 1998, pp. 47–50.
- Validating Critical Reagents Used in CGMP Analytical Testing. N. Ritter, M. Wiebe, May 2001, pp. 12–21.
- When Things Go Wrong: Part 1, The Consequences of Noncompliance. B.K. Immel, August 2000, pp. 38–44.
- When Things Go Wrong: Part 2, Encouragement for Tough Times. B.K. Immel, September 2001, pp. 40–46.
- Writing Procedures That Contribute to Performance. J.L. Vesper, August 2001, pp. 23–26.

Government Policies

- FDA and the Promise of FDAMA. L.A. Suydam, August 1999, pp. 43–45.
- Generic Biologics: Notes from the Path Less Traveled. B. Zeid, March 1999, pp. 24–32.
- Implementing the Biological Weapons Convention Protocol in the United States: What it Means to the Biopharmaceutical Industry. L.C. Klotz et al., August 2000, pp. 46–48.
- Stem Cells and Xenotransplantation: Ethics, Patents, and Politics — an Industry Roundtable. June 2002, pp. 19–22, 26–34.

Intellectual Property Rights

- 21 CFR Part 11: (Un)Expected Added Value. J.F. Noferi, D.E. Worden, R. Dillon, February 2002, pp. 44–50.
- Avoiding the Trademark Pitfalls of a Start-Up Company. R. Richards, August 1999, pp. 26–30.
- BIO Business: Performance, Not Promises. C.B. Feldbaum, June 2001, pp. 20–24.
- Bioinformatics Databases — Questions of Copyright. E. Howard, G. Ramsey, November 2002, pp. 46–48, 64.
- Client Confidentiality and Intellectual Property: Key Challenges in Outsourcing. M. Renn, K. Hall, C. Younger, November 2000, pp. 52–54.
- Criminal Penalties for Theft of Biological Materials. L. Howard, June 2002, pp. 64–66, 82.
- Generic Biologics: Notes from the Path Less Traveled. B. Zeid, March 1999, pp. 24–32.
- Outsourcing Biopharmaceutical Manufacturing Operations. S.H. Messing, June 1998, pp. 28–30.
- Patent Law You Can Use: Part 1, Types of Intellectual Property. H.M. Eisenberg, April 1999, pp. 38–39, 43.
- Viewpoint: BIOTECHNOLITICS: An Entrepreneur's Political Agenda. C.B. Feldbaum, June 1998, pp. 8–11.

International Business

- A Technology Transfer Story: Kangai's Recombinant Hepatitis B Vaccine. E. Wang, J. Wu, July 1999, pp. 20–21.
- Biotechnology in Developing Countries: A Technology Imperative. H. Padh, July 1999, pp. 18–19.
- Cell Bank Validation: Comparing Points to Consider and ICH Guidelines. M.S. Lao, January 1999, pp. 48–51.
- DO NOT Pass Go, DO NOT Collect 2,000 ECUs: The European Union's Centralized Procedure. A. Bowers, S. Hunter, March 2000, pp. 28–38.
- GMP, Compliance, and Regulatory Resources on the Worldwide Web: An Update. C. Scott, P.L. Cass, October 2000, pp. 58–62.

- Maturing Biomanufacturing Industry Offers Sponsors Clear Choices and Benefits. H.L. Levine, J.C. Miller, May 1999, pp. 62–64.
- Travel Notes: Snapshots of the Biopharmaceutical Industry in Baden-Württemberg. S.A. Montgomery, May 1998, pp. 22–23.
- Viewpoint: BioRegion — Using a Virtual Enterprise to Foster a Regional Biotech Industry. U. Jensen, May 1998, pp. 20–21.

Investigational New Drug Applications

- Comparability Analysis to Support a Manufacturing Site Change and Process Modifications for a Biopharmaceutical, T.L. Talarico, K.J. Guise, V.K. Garg, January 1999, pp. 42–47.
- Practices and Considerations in the Development of an Allogeneic Cellular Transplant. H.M. Nugent, A.M. Woodland, D. Deane, January 2001, pp. 36–41.

Legal Issues

- Bioinformatics Databases — Questions of Copyright. E. Howard, G. Ramsey, November 2002, pp. 46–48, 64.
- Biotechnology Patent Holders Beware! A Supreme Court Ruling may Significantly Reduce the Value of your Patent Portfolio. E.R. Ergenzinger Jr. W.M. Spruill, June 2002, pp. 58–62.
- Criminal Penalties for Theft of Biological Materials. L. Howard, June 2002, pp. 64–66, 82.
- DO NOT Pass Go, DO NOT Collect 2,000 ECUs: The European Union's Centralized Procedure. A. Bowers, S. Hunter, March 2000, pp. 28–38.
- Generic Biologics: Notes from the Path Less Traveled. B. Zeid, March 1999, pp. 24–32.
- Patent Law You Can Use: Part 1, Types of Intellectual Property. H.M. Eisenberg, April 1999, pp. 38–39, 43.
- Patent Law You Can Use: Part 2, Patents and Trade Secrets. H.M. Eisenberg, May 1999, pp. 50–51.
- Patenting Issues in Functional Genomics. C.R. Sutton, January 1998, pp. 42–44.
- Protecting Your Company's Trade Secrets. K.M. Parker, E.S. Pennington, October 1999, pp. 50–52.
- Restrictive Covenants: Protecting Confidential and Proprietary Information. C.A. Amalfe, K.R. Heslin, February 2000, pp. 52–56.
- Stem Cells and Xenotransplantation: Ethics, Patents, and Politics — An Industry Roundtable. , June 2002, pp. 19–22, 26–34.
- Survival Guide to FDA Inspections: Part 2, Conducting the Audit - Ready or Not, Here They Come. M. Lavian, P. W. Allen, October 2002, pp. 30–35.
- The IRS and the Independent Contractor: Knowing the Rules of the Game.

- A.E. Schultz, July 2001, pp. 24–26, 70.
- When Things Go Wrong: Part 1, The Consequences of Noncompliance. B.K. Immel, August 2000, pp. 38–44.

Legislation

- A Brief History of the GMPs: The Power of Storytelling. B.K. Immel, August 2000, pp. 26–36, 61.
- FDA and the Promise of FDAMA. L.A. Suydam, August 1999, pp. 43–45.
- Implementing the Biological Weapons Convention Protocol in the United States: What it Means to the Biopharmaceutical Industry. L.C. Klotz et al., August 2000, pp. 46–48.
- Liposomes, Liposomes (a Review): Part 1, Manufacturing Issues. S.S. Chrai, R. Murari, I. Ahmad, November 2001, pp. 10–14.
- Liposomes (a Review): Part 2, Drug Delivery Systems. S.S. Chrai, R. Murari, I. Ahmad, January 2002, pp. 40–43, 49.
- Nonviral Gene Delivery Systems: Part 2, Physical Characterization. T.J. Anchordoquy, September 1999, pp. 46–51.
- Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues. S.K. Das, K.J. Miller, November 1999, pp. 44–51.

Mammalian Cell Culture

- A Bovine Spongiform Encephalopathy Validation Study for Aprotinin and Bovine Serum Albumin. M. Blum et al., April 1998, pp. 28–34.
- Assessing a Disposable Bioreactor for Attachment-Dependent Cell Cultures. P.K. Namdev, P. Lio, February 2000, pp. 44–50.
- Assessment of Risk of Bovine Spongiform Encephalopathy in Pharmaceutical Products: Part 2, Example Risk Assessed for a Hypothetical Product. PhRMA BSE Committee, March 1998, pp. 18–30.
- Detection of Microbial Contamination in Cell Cultures Using a Laser Scanning System. A.O. Onadipe, April 2001, pp. 38–40.
- Employing Near-Infrared Spectroscopic Methods of Analysis for Fermentation Monitoring and Control: Part 1, Method Development. S.A. Arnold et al., November 2002, pp. 26–34.
- Evaluation of Two Bovine Cell Lines as Hosts for Detecting Several Common Bovine Viruses in Fetal Bovine Serum. Z.M. Plavsic, September 2000, pp. 48–51.
- Glycosylation of Human IgG Antibodies: Relevance to Therapeutic Applications. R. Jefferis, September 2001, pp. 19–27.
- Inactivation of Several Bovine Viruses in Fetal Bovine Serum Using pH Adjustments. Z.M. Plavsic et al., November 2000, pp. 34–38.

- Inactivation of Viruses and Mycoplasmas in Fetal Bovine Serum Using 56 °C Heat. D.J. Danner, J. Smith, June 1999, pp. 50–52.
- Production-Scale Qualification of a Novel Cell Culture Medium Format. R. Radominski et al., July 2001, pp. 34–39.
- Replacing the Animal Component in Serum: Evaluating Raw Materials for Inclusion in Optimized Hybridoma Media. S.C. Peppers et al., May 2001, pp. 22–30.
- Resistance of Porcine Circovirus to Gamma Irradiation. Z.M. Plavsic, S. Bolin, April 2001, pp. 32–36.
- Some Methods for Contamination Testing of a Master Cell Bank. M. Aleman et al., June 2000, pp. 48–52.
- Sterility Testing for Master Cell Banks, Working Cell Banks, and Unprocessed Bulk. G. Sofer, C. Phillips, September 2001, pp. 36–38.
- The Basics of Laboratory-Scale Mammalian Cell Cryopreservation. L. Wolfinbarger, October 1998, pp. 35–39.
- Transgenic Protein Production: The Technology and Major Players. P. Rohricht, March 1999, pp. 46–49.
- Transgenic Protein Production: Part 2, Process Economics. P. Rohricht, September 1999, pp. 52–54.
- Transgenics Go Commercial. M. Young, W.B. Okita, July 1998, pp. 24–28.
- Tutorial: Examining the Relationship Between Media and Light. W.H. Siegel, T. Pritchett, January 2000, pp. 65–66.

Media

- A Bovine Spongiform Encephalopathy Validation Study for Aprotinin and Bovine Serum Albumin. M. Blum et al., April 1998, pp. 28–34.
- Assessment of Risk of Bovine Spongiform Encephalopathy in Pharmaceutical Products: Part 2, Example Risk Assessed for a Hypothetical Product. PhRMA BSE Committee, March 1998, pp. 18–30.
- Customized Ligands Optimize Affinity Chromatography Procedures. L. Larsson, January 2001, pp. 42–44.
- Employing Near-Infrared Spectroscopic Methods of Analysis for Fermentation Monitoring and Control: Part 1, Method Development. S.A. Arnold et al., November 2002, pp. 26–34.
- Evaluation of Two Bovine Cell Lines as Hosts for Detecting Several Common Bovine Viruses in Fetal Bovine Serum. Z.M. Plavsic, September 2000, pp. 48–51.
- Homologous Recombination in CHO Cells. M. Reff, July 1998, pp. 33–34.
- Inactivating Adventitious Viruses While Preserving Biological Activity: Treating Fetal Bovine Serum with Pulsed Ultraviolet Light. M. Sawyer et al., December 2002, 35–40.

- Inactivation of Several Bovine Viruses in Fetal Bovine Serum Using pH Adjustments. Z.M. Plavsic et al., November 2000, pp. 34–38.
- Minimizing Risks from Chromatography Media: Management of Raw Materials in Biopharmaceutical Production. R.M. Kennedy, L. Gonzales, May 2001, pp. 56–58.
- Production-Scale Qualification of a Novel Cell Culture Medium Format. R. Radominski et al., July 2001, pp. 34–39.
- Replacing the Animal Component in Serum: Evaluating Raw Materials for Inclusion in Optimized Hybridoma Media. S.C. Peppers et al., May 2001, pp. 22–30.
- Storing an Ion-Exchange Chromatography Gel in Dilute Alkali During Recycling Improves Cleaning. J. Turton, Z. Moola, April 2002, pp. 24–30.
- Tutorial: Examining the Relationship Between Media and Light. W.H. Siegel, T. Pritchett, January 2000, pp. 65–66.

Microbial Fermentation

- Optimizing Recombinant Microbial Fermentation Processes: An Integrated Approach. M. Cserjan-Puschmann et al., July 2002, pp. 26–34.
- Pichia pastoris*: A Eukaryotic System for the Large-Scale Production of Biopharmaceuticals. C. Dale, A. Allen, S. Fogerty, November 1999, pp. 36–42.
- Stability of Proteins during Manufacture and Release from Biodegradable Polymers. R. Krishnamurthy, J.A. Lumpkin, January 1998, pp. 32–36.

Monoclonal Antibodies (MAbs)

- Considerations During Development of a Protein A-Based Antibody Purification Process. H. Iyer et al., January 2002, pp. 14–20, 53.
- Corn Seed Production of Therapeutic Proteins Moves Forward: One Company's Experience. J. Baez, D. Russell, J. Craig, August 2000, pp. 50–54.
- Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing: Part 1, Considerations for Technology Transfer and Commercial Development. S. Ford, W.E. Tente, October 2001, pp. 10–16.
- Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing: Part 2, A Case Study. S. Ford, W.E. Tente, November 2001, pp. 16–26.
- Encapsulated Antibody-Producing Cells for Long-Term Passive Immunotherapy. M. Pelegrin et al., October 1999, pp. 32–35.
- Glycosylation of Human IgG Antibodies: Relevance to Therapeutic Applications. R. Jefferis, September 2001, pp. 19–27.

- Immunogenicity: The Last Hurdle for Clinically Successful Therapeutic Antibodies. F. Adair, October 2000, pp. 42–46.
- Replacing the Animal Component in Serum: Evaluating Raw Materials for Inclusion in Optimized Hybridoma Media. S.C. Peppers et al., May 2001, pp. 22–30.
- Spectroscopic Determination of Chelator Content in Antibody–Chelator Conjugates. E. Dadachova, November 2000, pp. 40–44.
- The Future and the Biotechnology Industry: New Trends in Pharmaceutical Development. M.D. Dibner, June 2001, pp. 26–30.
- Viral Clearance Strategies for Biopharmaceutical Safety: Part 3, A Multifaceted Approach to Process Validation. H. Aranha, S. Forbes, May 2001, pp. 42–54, 90.

Monoclonal Antibody Recovery

- Large-Scale Production of a Monoclonal IgM in a Hybridoma Suspension Culture. M.A. Cacciuto et al., April 1998, pp. 20–27.

New Drug Applications

- One Product, One Process, One Set of Specifications: A Proven Quality Paradigm for the Safety and Efficacy of Biologic Drugs. T. Copmann et al., March 2001, pp. 14–24.
- The FDA Regulatory Methods Validation Program for New and Abbreviated New Drug Applications. T. Layloff et al., January 2000, pp. 30–38.

Oligonucleotides

- Glycobiology is Growing. J.C. Klock, July 1998, pp. 31–33.
- Nonviral Gene Delivery Systems: Part 2, Physical Characterization. T.J. Anchordoquy, September 1999, pp. 46–51.
- Nucleic Acid Drug Delivery: Part 1, Delivery Issues Related to Dividing Cells. S. Wu-Pong, D.A. Gewirtz, November 1998, pp. 28–35.
- Nucleic Acid Drug Delivery: Part 2, Delivery to the Brain. S. Wu-Pong, D.A. Gewirtz, January 1999, pp. 32–38.
- Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues. S.K. Das, K.J. Miller, November 1999, pp. 44–51.

Patents

- Biotechnology Patent Holders Beware! A Supreme Court Ruling may Significantly Reduce the Value of your Patent Portfolio. E.R. Ergenzinger Jr., W.M. Spruill, June 2002, pp. 58–62.
- Patent Law You Can Use: Part 1, Types of Intellectual Property. H.M. Eisenberg, April 1999, pp. 38–39, 43.
- Patent Law You Can Use: Part 2, Patents and Trade Secrets. H.M. Eisenberg, May 1999, pp. 50–51.

- Patenting Issues in Functional Genomics.
C.R. Sutton, January 1998, pp. 42–44.
- Sale of Your Product Can Prevent Patenting:
How to Avoid the On-Sale Bar. T. Brody,
February 2002, pp. 38–42.
- Stem Cells and Xenotransplantation: Ethics,
Patents, and Politics — An Industry Round-
table. , June 2002, pp. 19–22, 26–34.

Personnel Issues

- Creating Effective Biopharmaceutical QA/QC
Organizations: Your People are the Key.
E.R. Arling, R. Dillon, J.F. Noferi, June 2002,
pp. 40–46.
- Our Ways Are Numbered: Surveying
BioPharm's Readers. P.L. Cass, June 2001,
pp. 59–63.
- Science or Project Management: What (and
Who) Is More Important in Biotech?,
July 2001, pp. 28–29.
- Surveying the Field: Your Career in the
Biopharmaceutical Industry. A. Muir,
May 1999, pp. 28–36.
- Survival Guide to FDA Inspections: Part 2,
Conducting the Audit - Ready or Not, Here
They Come. M. Lavian, P.W. Allen,
October 2002, pp. 30–35.
- When Things Go Wrong: Part 2, Encourage-
ment for Tough Times. B.K. Immel,
September 2001, pp. 40–46.

Plant Biotechnology

- Biopharmaceutical Production in Transgenic
Plants: Toward Development of Regulatory
Guidelines. B.J. Price, July 1999, p. 28.
- Corn Seed Production of Therapeutic Proteins
Moves Forward: One Company's Experi-
ence. J. Baez, D. Russell, J. Craig,
August 2000,
pp. 50–54.
- The Business of Doing Business. R. Leach,
July 1999, pp. 29.
- The Future and the Biotechnology Industry:
New Trends in Pharmaceutical Develop-
ment. M.D. Dibner, June 2001, pp. 26–30.
- Two Crops, One Plant. B. Hooker, July 1999,
pp. 29–30.

Posttranslational Processing

- Glycosylation of Human IgG Antibodies:
Relevance to Therapeutic Applications.
R. Jefferis, September 2001, pp. 19–27.
- Pichia pastoris*: A Eukaryotic System for the
Large-Scale Production of Biopharmaceuti-
cals. C. Dale, A. Allen, S. Fogerty,
November 1999, pp. 36–42.

Process Automation

- CGMP Pharmaceutical Scale-Up: Part 3,
Automation. M. Patel, C. Pepper,
H. Hartounian, November 1999,
pp. 52–54.

- Throughput Analysis and Debottlenecking of
Biomanufacturing Facilities: A Job for
Process Simulators. D. Petrides, A. Koulouris,
C. Siletti, August 2002, pp. 28–34, 64.

Process Control/Monitoring

- A Guide to Determining Sample Sizes and
Outlier Criteria in Analytical Investigations.
J.D. Hofer, E.C. Rickard, May 2001,
pp. 32–41, 68.
- Blow-Fill-Seal Technology: Design Optimiza-
tion of a Particulate Control System. J. Price,
April 1999, pp. 25–29, 43.
- CGMP Pharmaceutical Scale-Up: Part 4,
Installation, Commissioning, Development.
C. Pepper, M. Patel, H. Hartounian,
February 2000, pp. 28–34.
- Defining Critical Variables in Well-Character-
ized Biotechnology Processes. R.J. Seely
et al., April 1999, pp. 33–36.
- Demonstrating Product Comparability.
H.K.B. Simmerman, September 2000,
pp. 58–62.
- Designs for Bioassays with Plate Location
Effects. B. Schlain et al., November 2001,
pp. 40–44.
- Detection of Microbial Contamination in Cell
Cultures Using a Laser Scanning System.
A.O. Onadipe, April 2001, pp. 38–40.
- Effect of Heat Treatment on Four Viruses
Inoculated into BSA and Bovine Transferrin
Solution. Z.M. Plavsic, June 2000,
pp. 54–56.
- Elements of Downstream Bioprocess Valida-
tion. N.M. Lugo, June 1998, pp. 18–26.
- Employing Near-Infrared Spectroscopic
Methods of Analysis for Fermentation
Monitoring and Control: Part 1, Method
Development. S.A. Arnold et al.,
November 2002, pp. 26–34.
- Environmental Control and Monitoring in Bulk
Manufacturing Facilities for Biological
Products. J. Barta, May 1998, pp. 84–89.
- Freezing Bulk-Scale Biopharmaceuticals Using
Common Techniques — and the
Magnitude of Freeze-Concentration.
S.D. Webb et al., May 2002, pp. 22–34.
- GMP Compliance from a Production
Manager's Point of View. M. Pemberton,
August 1998, pp. 34–37.
- Integrating New Technology into Blood
Plasma Fractionation. J. Curling,
September 2002, pp. 16–26.
- Large-Scale Cryopreservation of Cells, Cell
Components, and Biological Solutions.
R. Wisniewski, September 1998,
pp. 42–49, 61.
- Learning from Bioburden Count Distributions.
D.W. Cooper, March 1998, pp. 32–37.
- Making Better Decisions: Troubleshooting
Biopharmaceutical Processes Using Problem
Analysis. J.A. Myers, October 2000,
pp. 32–35.
- Master Planning and Validation: Part 1,
Anatomy of a Validation Master Plan.
J. Agalloco, March 2000, pp. 40–44, 70.
- Monitoring and Controlling Biocatalytic
Processes: Inhibiting Biocatalysts at Useful
Reactant and Product Concentrations.
P.A. Bird, D.C.A. Sharp, and J.M. Woodley,
December 2002, pp. 14–21.
- Optimizing Recombinant Microbial Fermenta-
tion Processes: An Integrated Approach.
M. Cserjan-Puschmann et al., July 2002,
pp. 26–34.
- Pharmaceutical Companies Provide Unique
Contract Service Capabilities. S. Fox,
July 2000, pp. 30–34.
- Planning Ahead for Manufacturing Facility
Changes: A Case Study in Outsourcing.
M. Katz, January 2001, pp. 46–47, 56.
- Process Hazard Analysis and Critical Control
Point Identification. C. DeSain, C. Sutton,
October 2000, pp. 36–40.
- Process Validation: How Much to Do and
When to Do It. A.S. Rathore et al.,
October 2002, pp. 18–28.
- Rapid Process Development for Biopharma-
ceutical Manufacture. D. Byrom, July 1999,
pp. 26–29.
- Risk Management and Liability for Biologics.
C.S. Ryan, M. Wan, July 2000, pp. 40–42.
- Software for Biopharmaceutical Companies.
C. Scott, February 1999, pp. 22–32.
- Statistical Tools for Setting In-Process Accep-
tance Criteria. R.J. Seely, L. Muniyakazi,
J. Hauri, October 2001, pp. 28–34.
- The Compliance Costs of Hasty Process
Development. G. Bobrowicz, August 1999,
pp. 35–38.
- The Evolving Role of Product Characterization
During Development. J. Faulkner,
June 2000, pp. 26–34.
- Tutorial: Establishing a Calibration
Management Program. D.M. Evans,
J. Erickson, May 1998, pp. 105–106.
- Tutorial: Establishing Calibration Intervals,
Traceability, and Documentation.
D.M. Evans, J. Erickson, June 1998,
pp. 73–74.
- Tutorial: The Importance of Time Variables in
Temperature Studies. P. A. Hugunin,
G. Straub, February 2000, pp. 73–74.
- Validation of Quantitative PCR Assays:
Addressing Virus Contamination Concerns.
A. Lovatt et al., March 2002, pp. 22–32.
- Viral Clearance Strategies for Biopharmaceuti-
cal Safety: Part 1, General Considerations.
H. Aranha, January 2001, pp. 28–35.

Protein Denaturation

- Developing Large-Scale Cryopreservation
Systems for Biopharmaceutical Products.
R. Wisniewski, June 1998, pp. 50–60.
- Large-Scale Cryopreservation of Cells, Cell
Components, and Biological Solutions.

R. Wisniewski, September 1998, pp. 42–49, 61.

Protein Stability in Pulmonary Delivery Formulations: A Review. R. Krishnamurthy, March 1999, pp. 34–38.

Stability of Proteins during Manufacture and Release from Biodegradable Polymers. R. Krishnamurthy, J.A. Lumpkin, January 1998, pp. 32–36.

Protein Folding

Differential Scanning Calorimetry: A Practical Tool for Elucidating Stability of Liquid Biopharmaceuticals. R.L. Remmele Jr., W.R. Gombotz, June 2000, pp. 36–46.

Protein Precipitation

Determining Protein Concentration: Part 1, Methodology. N. Ritter, J. McEntire, April 2002, pp. 12–22, 58.

Protein Sequencing, A Historical Perspective. M.J. Suto, February 1998, pp. 28–30.

Drug Discovery: Affinity and Beyond. N. Janjic, February 1998, pp. 28.

Immunogenicity: The Last Hurdle for Clinically Successful Therapeutic Antibodies. F. Adair, October 2000, pp. 42–46.

Mainstreaming the Technology. M. Hediger, February 1998, pp. 32, 43.

RNA as a Small-Molecule Drug Target. D.J. Ecker, February 1998, pp. 26–27.

Protein/Polypeptide Recovery

Stability of Proteins during Manufacture and Release from Biodegradable Polymers. R. Krishnamurthy, J.A. Lumpkin, January 1998, pp. 32–36.

Public Policy, A Brief History of the GMPs: The Power of Storytelling. B.K. Immel, August 2000, pp. 26–36, 61.

QA/QC

A Practical Approach to Investigating GMP Failures. J.F. Huxsoll, August 1999, pp. 39–42.

Assessment of Risk of Bovine Spongiform Encephalopathy in Pharmaceutical Products, Part 1. PhRMA: BSE Committee, January 1998, pp. 20–31, 56.

A System Developer's Approach to Validation. C.L. Gent, March 2002, pp. 46–50, 72.

Beyond QSIT. J.F. Noferi, E.R. Arling, D.E. Worden, April 2002, pp. 40–44, 67.

Bioburden Determinations: Most Probable Number or Colony Counting? D.W. Cooper, June 1999, pp. 53–55, 90.

Comparability Analysis to Support a Manufacturing Site Change and Process Modifications for a Biopharmaceutical, T.L. Talarico, K.J. Guise, V.K. Garg, January 1999, pp. 42–47.

Creating Effective Biopharmaceutical QA/QC Organizations: Your People are the Key.

E.R. Arling, R. Dillon, J.F. Noferi, June 2002, pp. 40–46.

Defining Your GMP Training Program with a Training Procedure. J.L. Vesper, November 2000, pp. 28–32.

Demonstrating Product Comparability. H.K.B. Simmerman, September 2000, pp. 58–62.

Designs for Bioassays with Plate Location Effects. B. Schlain et al., November 2001, pp. 40–44.

Documentation: It's Not Just Paper Work. D. Feuerhelm, G.S. Blank, August 2001, pp. 18–21, 64.

Employing Near-Infrared Spectroscopic Methods of Analysis for Fermentation Monitoring and Control: Part 1, Method Development. S.A. Arnold et al., November 2002, pp. 26–34.

Environmental Control and Monitoring in Bulk Manufacturing Facilities for Biological Products. J. Barta, May 1998, pp. 84–89.

Facilitating Client Audits: The Contract Laboratory Perspective. B. Carter-Hamm, G. Vinson, July 2002, pp. 12–16.

Implementing 21 CFR Part 11 in Analytical Laboratories: Part 5, The Importance of Instrument Control and Data Acquisition. W. Winter, L. Huber, September 2000, pp. 52–56.

Improving the ESD Procedure for Outlier Testing. M.A. Djauhari, March 2001, pp. 42–46.

Information Age Audits. J.F. Noferi, D.E. Worden, E.R. Arling, January 2002, pp. 35–39, 50.

Keys to Quality Systems for Handling Investigations: Investigating, Documenting, and Resolving Problems. M.L. Balboni, August 2001, pp. 12–17, 63.

Making Better Decisions: Troubleshooting Biopharmaceutical Processes Using Problem Analysis. J.A. Myers, October 2000, pp. 32–35.

Making Regulatory Compliance a Core Process: Director and Officer Liability Exposure. J.F. Noferi et al., August 2002, pp. 35–41.

Meeting the Challenges of Enzyme Assay Validation. U. Patel, July 2000, pp. 48–52.

Minimizing Risks from Chromatography Media: Management of Raw Materials in Biopharmaceutical Production. R.M. Kennedy, L. Gonzales, May 2001, pp. 56–58.

Performance: The Goal of Training or Why Training is Not Always the Answer . . . J.L. Vesper, February 2001, pp. 44–46.

Preparing Biological Product Deviation Reports: Suggestions for Manufacturers. B.W. Unger, October 2002, pp. 36–40.

Process Hazard Analysis and Critical Control Point Identification. C. DeSain, C. Sutton, October 2000, pp. 36–40.

Process Validation: How Much to Do and When to Do It. A.S. Rathore et al., October 2002, pp. 18–28.

Reexamining the "Set It and Forget It" Approach. P. Poulter, September 2002, pp. 14–15, 65.

Regulatory Requirements for Somatic Cell Therapy Products: Safety Concerns and Practical Solutions. M.S. Lao, March 2000, pp. 50–55.

Replacing Slab Gel Electrophoresis Methods with Capillary Electrophoresis for Quality Control and Stability Testing. S.H. Bowen, M.A. Schenerman, November 1998, pp. 42–46, 50.

Risk Management and Liability for Biologics. C.S. Ryan, M. Wan, July 2000, pp. 40–42.

Setting Biopharmaceutical Specifications. J. Cohen, M. Busch, August 1998, pp. 38–42.

Specifications and Manufacturing Change Control: A Prototypic System for Electronic Document Tracking and Management. R. Zeid, March 2002, pp. 34–44.

Spectroscopic Determination of Chelator Content in Antibody–Chelator Conjugates. E. Dadachova, November 2000, pp. 40–44.

Strategies for Host Cell Protein Analysis. K. Hoffman, May 2000, pp. 38–45.

Successful Technology Transfer: Lessons from Experience. C.J. Dale, October 2000, pp. 48–56.

Survival Guide to FDA Inspections: Part 1, To Prepare or Not to Prepare, There is No Question. M. Lavian, P. W. Allen, August 2002, pp. 20–26, 49.

Technical Note: An Exact Test for Outlier Detection. M.A. Djauhari, June 1999, pp. 56–59.

The Integration of Design, Construction, and Validation: Solving a Validation Challenge. J.N. Odum, November 1998, pp. 36–41.

Tutorial: Establishing a Calibration Management Program. D.M. Evans, J. Erickson, May 1998, pp. 105–106.

Tutorial: Exploiting the Poisson Distribution for Bioburden Investigations. D.W. Cooper, April 2000, pp. 65–66.

Tutorial: In Search of Standardized Definitions for Validation, Qualification, Verification, and Calibration. L. Huber, April 1999, pp. 56–58.

Tutorial: Preparation and Qualification of Certified Reference Materials and Working Standards. L. Huber, June 1999, pp. 84–86.

Tutorial: Qualification of Legacy Equipment in Quality Control Laboratories. L.E. Little, March 1998, pp. 61–62.

Tutorial: Qualification of Quality Control Laboratory Equipment. T.J. Pritchett, January 1998, pp. 57–58.

- Tutorial: Qualification of UV-Visible Spectrophotometers. T. Owen, January 1999, pp. 62–66, 25.
- Tutorial: Qualifying High-Performance Capillary Electrophoresis Systems. G.A. Ross, November 1999, pp. 81–82.
- Tutorial: Systems Qualification for High-Performance Liquid Chromatography Systems. L. Huber, November 1998, pp. 65–66, 41.
- Two Statistical Methods for Estimating Relative Potency of Bioassays. R. Reeve, July 2000, pp. 54–60.
- Using a Model and Tools to Standardize the Preparation for a Preapproval Inspection. B.W. Unger, February 2002, pp. 14–18, 71.
- Validating a Refrigerator-Freezer. P. A. Cloud, November 1998, pp. 47–50.
- Validating Computer Systems for Clinical Trials, Part 1. G. Benghiat, A. Miller, January 1999, pp. 39–41.
- When Things Go Wrong: Part 1, The Consequences of Noncompliance. B.K. Immel, August 2000, pp. 38–44.
- Regulatory Issues**
- 21 CFR Part 11: (Un)Expected Added Value. J.F. Noferi, D.E. Worden, D.E. Worden, February 2002, pp. 44–50.
- A Brief History of the GMPs: The Power of Storytelling. B.K. Immel, August 2000, pp. 26–36, 61.
- A Practical Approach to Investigating GMP Failures. J.F. Huxsoll, August 1999, pp. 39–42.
- Announcing USP Chapter <1046>, "Cell and Gene Therapy Products". S. Seaver, January 2000, pp. 26–29.
- Assessment of Risk of Bovine Spongiform Encephalopathy in Pharmaceutical Products: Part 2, Example Risk Assessed for a Hypothetical Product. PhRMA BSE Committee, March 1998, pp. 18–30.
- Beyond QSIT. J.F. Noferi, E.R. Arling, April 2002, pp. 40–44, 67.
- BIO Business: Performance, Not Promises. C.B. Feldbaum, June 2001, pp. 20–24.
- Biopharmaceutical Shipping: Moving at the Speed of Life. J. Johnson, March 2001, pp. 34–36.
- Cell and Tissue Therapies: Working with Complex, Mutable, Living Entities. N. Chew, April 2001, pp. 20–24, 66.
- Cell Bank Validation: Comparing Points to Consider and ICH Guidelines. M.S. Lao, January 1999, pp. 48–51.
- Clinical Programs in Cutting-Edge Technologies: A Guide for Beginning the Development of Novel Therapies. M. Wade, May 1998, pp. 52–56.
- Comparability Analysis to Support a Manufacturing Site Change and Process Modifications for a Biopharmaceutical, T.L. Talarico, K.J. Guise, V.K. Garg, January 1999, pp. 42–47.
- Creating Effective Biopharmaceutical QA/QC Organizations: Your People are the Key. E.R. Arling, R. Dillon, J.F. Noferi, June 2002, pp. 40–46.
- Defining Critical Variables in Well-Characterized Biotechnology Processes. R.J. Seely et al., April 1999, pp. 33–36.
- Defining Your GMP Training Program with a Training Procedure. J.L. Vesper, November 2000, pp. 28–32.
- Demonstrating Product Comparability. H.K.B. Simmerman, September 2000, pp. 58–62.
- Design and Validation of Isolator Systems for the Manufacturing and Testing of Health Care Products: Highlights from the New PDA Technical Report No. 34. R.E. Madsen, July 2001, pp. 30–32.
- Documentation: It's Not Just Paper Work. D. Feuerhelm, G.S. Blank, August 2001, pp. 18–21, 64.
- Determining the Useful Lifetime of Chromatography Resins: Prospective Small-Scale Studies. R.M. O'Leary et al., September 2001, pp. 10–18.
- DO NOT Pass Go, DO NOT Collect 2,000 ECUs: The European Union's Centralized Procedure. A. Bowers, S. Hunter, March 2000, pp. 28–38.
- Documentation: It's Not Just Paper Work. D. Feuerhelm, G.S. Blank, August 2001, pp. 18–21, 64.
- Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing: Part 1, Considerations for Technology Transfer and Commercial Development. S. Ford, W.E. Tente, October 2001, pp. 10–16.
- Ensuring Laboratory Compliance. R.H. Johnson, August 1998, pp. 30–32.
- Facilitating Client Audits: The Contract Laboratory Perspective. B. Carter-Hamm, G. Vinson, July 2002, pp. 12–16.
- FDA and the Promise of FDAMA. L.A. Suydam, August 1999, pp. 43–45.
- From R&D to Licensing: What to Do and When to Do it. G. Sofer, January 2001, pp. 18–27.
- Generic Biologics: Notes from the Path Less Traveled. B. Zeid, March 1999, pp. 24–32.
- GMP Compliance from a Production Manager's Point of View. M. Pemberton, August 1998, pp. 34–37.
- GMP, Compliance, and Regulatory Resources on the Worldwide Web: An Update. C. Scott, P. L. Cass, October 2000, pp. 58–62.
- Implementing 21 CFR Part 11 in Analytical Laboratories: Part 1, Overview and Requirements. L. Huber, November 1999, pp. 28–34.
- Implementing 21 CFR Part 11 in Analytical Laboratories: Part 2, Security Aspects for Systems and Applications. W. Winter, L. Huber, January 2000, pp. 44–50.
- Implementing 21 CFR Part 11 in Analytical Laboratories: Part 3, Ensuring Data Integrity in Electronic Records. W. Winter, L. Huber, March 2000, pp. 45–49.
- Implementing 21 CFR Part 11 in Analytical Laboratories: Part 4, Data Migration and Long-Term Archiving for Ready Retrieval. L. Huber, W. Winter, June 2000, pp. 58–64.
- Implementing 21 CFR Part 11 in Analytical Laboratories: Part 5, The Importance of Instrument Control and Data Acquisition. W. Winter, L. Huber, September 2000, pp. 52–56.
- Implementing the Biological Weapons Convention Protocol in the United States: What it Means to the Biopharmaceutical Industry. L.C. Klotz et al., August 2000, pp. 46–48.
- Improving Your Training Program. B. Immel, August 1999, pp. 31–34.
- Information Age Audits. J.F. Noferi, D.E. Worden, E.R. Arling, January 2002, pp. 35–39, 50.
- Keys to Quality Systems for Handling Investigations: Investigating, Documenting, and Resolving Problems. M.L. Balboni, August 2001, pp. 12–17, 63.
- Making Regulatory Compliance a Core Process: Director and Officer Liability Exposure. J.F. Noferi et al., August 2002, pp. 35–41.
- Minimizing Risks from Chromatography Media: Management of Raw Materials in Biopharmaceutical Production. R.M. Kennedy, L. Gonzales, May 2001, pp. 56–58.
- Multiuse Chromatography System: A Clean-in-Place Validation Case Study. P. A. Garipey, R.S. Moore, G. Sofer, September 1998, pp. 32–36.
- One Product, One Process, One Set of Specifications: A Proven Quality Paradigm for the Safety and Efficacy of Biologic Drugs. T. Copmann et al., March 2001, pp. 14–24.
- Practices and Considerations in the Development of an Allogeneic Cellular Transplant. H.M. Nugent, A.M. Woodland, D. Deane, January 2001, pp. 36–41.
- Preparing Biological Product Deviation Reports: Suggestions for Manufacturers. B.W. Unger, October 2002, pp. 36–40.
- Process Hazard Analysis and Critical Control Point Identification. C. DeSain C. Sutton, October 2000, pp. 36–40.
- Project Management of Small R&D Companies: Part 1, Perspective from a Large CRO. F. Beddia et al., February 2001, pp. 26–28.
- Qualification of Network Components and Validation of Networked Systems. L. Huber, R. Budihandjo, October 2001, pp. 18–26, 46.

- Regulatory Aspects of Column Chromatography in Biopharmaceutical Manufacturing: U.S. and EU Regulatory Attitudes Toward Change. M. Behizad, D. Baines, May 1998, pp. 72–82.
- Regulatory Requirements for Somatic Cell Therapy Products: Safety Concerns and Practical Solutions. M.S. Lao, March 2000, pp. 50–55.
- Resistance of Porcine Circovirus to Gamma Irradiation. Z.M. Plavsic, S. Bolin, April 2001, pp. 32–36.
- Responding to FDA-483's and Warning Letters. D.L. Chesney, A.E. Kelly, October 1998, pp. 26–29.
- Risk Management and Liability for Biologics. C.S. Ryan, M. Wan, July 2000, pp. 40–42.
- Setting Biopharmaceutical Specifications. J. Cohen, M. Busch, August 1998, pp. 38–42.
- Specifications and Manufacturing Change Control: A Prototypic System for Electronic Document Tracking and Management. R. Zeid, March 2002, pp. 34–44.
- Stepwise Implementation of CGMPs: A "GSP" Approach. L.E. Little, September 1998, pp. 37–41.
- Sterility Testing for Master Cell Banks, Working Cell Banks, and Unprocessed Bulk. G. Sofer, C. Phillips, September 2001, pp. 36–38.
- Survival Guide to FDA Inspections: Part 1, To Prepare or Not to Prepare, There is No Question. M. Lavian, P.W. Allen, August 2002, pp. 20–26, 49.
- Survival Guide to FDA Inspections: Part 2, Conducting the Audit — Ready or Not, Here They Come. M. Lavian, P.W. Allen, October 2002, pp. 30–35.
- Survival Guide to FDA Inspections: Part 3, Responding to Observations. M. Lavian, P.W. Allen, November 2002, pp. 42–44.
- Survival: It's All About Compliance. C. Scott, L. McLeod, October 2000, pp. 65–67.
- The FDA Regulatory Methods Validation Program for New and Abbreviated New Drug Applications. T. Layloff et al., January 2000, pp. 30–38.
- The Nuts and Bolts of FDA Inspections: Before, During, and After. J.R. Christensen, August 1998, pp. 44–46.
- The Reemergence of the Biopharmaceutical Contract Manufacturing Industry. R.L. McKown, May 1999, pp. 54–57.
- Tutorial: Implementing and Managing Calibration Training. D.M. Evans, J. Erickson, October 1998, pp. 57–58.
- Tutorial: Qualification of UV-Visible Spectrophotometers. T. Owen, January 1999, pp. 62–66, 25.
- Tutorial: System Suitability Testing. S.S. Kuwahara, September 1998, pp. 65–66.
- Using a Model and Tools to Standardize the Preparation for a Preapproval Inspection. B.W. Unger, February 2002, pp. 14–18, 71.
- Validating Computer Systems for Clinical Trials, Part 1. G. Benghiat, A. Miller, January 1999, pp. 39–41.
- Viral Clearance Strategies for Biopharmaceutical Safety: Part 3, A Multifaceted Approach to Process Validation. H. Aranha, S. Forbes, May 2001, pp. 42–54, 90.
- When Things Go Wrong: Part 1, The Consequences of Noncompliance. B.K. Immel, August 2000, pp. 38–44.
- When Things Go Wrong: Part 2, Encouragement for Tough Times. B.K. Immel, September 2001, pp. 40–46.
- Writing Procedures That Contribute to Performance. J.L. Vesper, August 2001, pp. 23–26.
- You Have Failed . . . A Case Study in Warning Letter Remediation. J.F. Noferi et al., November 2002, pp. 35–40, 64.

Scale-up Strategies

- Assessing a Disposable Bioreactor for Attachment-Dependent Cell Cultures. P.K. Namdev, P. Lio, February 2000, pp. 44.
- CGMP Pharmaceutical Scale-Up: Part 1, Design. C. Pepper, M. Patel, H. Hartounian, September 1999, pp. 26–34.
- CGMP Pharmaceutical Scale-Up: Part 3, Automation. M. Patel, C. Pepper, H. Hartounian, November 1999, pp. 52–54.
- CGMP Pharmaceutical Scale-Up: Part 4, Installation, Commissioning, Development. C. Pepper, M. Patel, H. Hartounian, February 2000, pp. 28–34.
- Considerations During Development of a Protein A-Based Antibody Purification Process. H. Iyer et al., January 2002, pp. 14–20, 53.
- Customized Ligands Optimize Affinity Chromatography Procedures. L. Larsson, January 2001, pp. 42–44.
- Developing Large-Scale Cryopreservation Systems for Biopharmaceutical Products. R. Wisniewski, June 1998, pp. 50–60.
- Freezing Bulk-Scale Biopharmaceuticals Using Common Techniques — and the Magnitude of Freeze-Concentration. S.D. Webb et al., May 2002, pp. 22–34.
- Increased Adenoviral Vector Production: Scaling Up 293 Cells in a Packed-Bed Bioreactor. G.G. Wang, W. Zhang, July 1999, pp. 24–26.
- Ion-Exchange Displacement Chromatography: Scale-Up and Displacer Clearance for Recombinant Human Brain-Derived Neurotrophic Factor (rHuBDNF). K.A. Barnt-house, W. Trompeter, September 1999, pp. 35–44.
- Monitoring and Controlling Biocatalytic Processes: Inhibiting Biocatalysts at Useful

- Reactant and Product Concentrations. P.A. Bird, D.C.A. Sharp, and J.M. Woodley, December 2002, pp. 14–21.
- Optimizing Recombinant Microbial Fermentation Processes: An Integrated Approach. M. Cserjan-Puschmann et al., July 2002, pp. 26–34.
- Purifying the Sendai Virus in One Step Using Ion-Exchange Chromatography. J. Eveleth et al., January 2000, pp. 40–43.
- Statistical Tools for Setting In-Process Acceptance Criteria. R.J. Seely, L. Munyakazi, J. Haury, October 2001, pp. 28–34.
- Systematic Troubleshooting for LC/MS/MS: Part 2, Large-Scale LC/MS/MS and Automation. N. Weng, T.D.J. Halls, January 2002, pp. 22–26, 49.
- The Basics of Laboratory-Scale Mammalian Cell Cryopreservation. L. Wolfinbarger, October 1998, pp. 35–39.
- The Industrial Production Costs of Recombinant Therapeutic Proteins Expressed in Transgenic Corn. D. Mison, J. Curling, May 2000, pp. 48–54.
- The Squeeze in Contract Biomanufacturing. R. Lias, S. Fogerty, July 2001, pp. 18–22.
- Transgenic Protein Production. P. Rohricht, March 1999, pp. 46–49.
- Transgenic Protein Production: Part 2, Process Economics. P. Rohricht, September 1999, pp. 52–54.
- Transgenics Go Commercial. M. Young, W.B. Okita, July 1998, pp. 24–28.
- Validation of Large-Scale Chromatographic Processes: Part 1, Case Study of Neuleze Capture on Macroprep High-S. T.N. Breece, E. Gilkerson, C. Schmelzer, May 2002, pp. 16–20.

Separation and Purification

- Comparing the Safety of Synthetic and Biological Ligands Used for Purification of Therapeutic Proteins. M. Behizad, J.M. Curling, September 2000, pp. 42–46.
- Defining Critical Variables in Well-Characterized Biotechnology Processes. R.J. Seely et al., April 1999, pp. 33–36.
- Ion-Exchange Displacement Chromatography: Scale-Up and Displacer Clearance for Recombinant Human Brain-Derived Neurotrophic Factor (rHuBDNF). K.A. Barnt-house, W. Trompeter, September 1999, pp. 35–44.
- Process Purification of Polypeptides and Proteins by Reversed-Phase Column Chromatography: Misconceptions and Reality. P. Lu et al., September 2001, pp. 28–35.
- Purifying the Sendai Virus in One Step Using Ion-Exchange Chromatography. J. Eveleth et al., January 2000, pp. 40–43.
- Systematic Troubleshooting for LC/MS/MS: Part 1, Sample Preparation and Chromatography. N. Weng, T.D.J. Halls, November 2001, pp. 28–38.

Validation of Large-Scale Chromatographic Processes: Part 2, Results from the Case Study of Neuleze Capture on Macroprep High-S. T.N. Breece, E. Gilkerson, C. Schmelzer, July 2002, pp. 35-42.

Sera and Serum Substitutes

Assessment of Risk of Bovine Spongiform Encephalopathy in Pharmaceutical Products, Part 1. PhRMA: BSE Committee, January 1998, pp. 21-31, 56.

Effect of Heat Treatment on Four Viruses Inoculated into BSA and Bovine Transferrin Solution. Z.M. Plavsic, June 2000, pp. 54-56.

Inactivating Adventitious Viruses While Preserving Biological Activity: Treating Fetal Bovine Serum with Pulsed Ultraviolet Light. M. Sawyer et al., December 2002, 35-40.

Inactivation of Viruses and Mycoplasmas in Fetal Bovine Serum Using 56 °C Heat. D.J. Danner, J. Smith, M. Plavsic, June 1999, pp. 50-52.

Integrating New Technology into Blood Plasma Fractionation. J. Curling, September 2002, pp. 16-26.

Replacing the Animal Component in Serum: Evaluating Raw Materials for Inclusion in Optimized Hybridoma Media. S.C. Peppers et al., May 2001, pp. 22-30.

Standard Operating Procedures

Beating the Documentation Blues. B. Immel, August 1998, pp. 47-51.

Defining Your GMP Training Program with a Training Procedure. J.L. Vesper, November 2000, pp. 28-32.

Master Planning and Validation: Part 2, System Definition. J. Agalloco, April 2000, pp. 34-38.

Preparing Biological Product Deviation Reports: Suggestions for Manufacturers. B.W. Unger, October 2002, pp. 36-40.

Preparing for Team Biologics Inspections: Improving Your Chances of Success. R.F. Tetzlaff, August 1998, pp. 18-28.

Setting Biopharmaceutical Specifications. J. Cohen, M. Busch, August 1998, pp. 38-42.

Successful Technology Transfer: Lessons from Experience. C.J. Dale, October 2000, pp. 48-56.

Survival Guide to FDA Inspections: Part 2, Conducting the Audit - Ready or Not, Here They Come. M. Lavian, P. W. Allen, October 2002, pp. 30-35.

Tutorial: Qualification of Legacy Equipment in Quality Control Laboratories. L.E. Little, March 1998, pp. 61-62.

Validating Critical Reagents Used in CGMP Analytical Testing. N. Ritter, M. Wiebe, May 2001, pp. 12-21.

Writing Procedures That Contribute to Performance. J.L. Vesper, August 2001, pp. 23-26.

Statistics

A Guide to Determining Sample Sizes and Outlier Criteria in Analytical Investigations. J.D. Hofer, E.C. Rickard, May 2001, pp. 32-41, 68.

Improving the ESD Procedure for Outlier Testing. M.A. Djauhari, March 2001, pp. 42-46.

Learning from Bioburden Count Distributions. D.W. Cooper, March 1998, pp. 32-37.

Statistics for Laboratory Method Comparison Studies. R.T. Magari, January 2002, pp. 28-32.

Transgenics

Clinical Programs in Cutting-Edge Technologies: A Guide for Beginning the Development of Novel Therapies. M. Wade, May 1998, pp. 52-56.

Corn Seed Production of Therapeutic Proteins Moves Forward: One Company's Experience. J. Baez, D. Russell, J. Craig, August 2000, pp. 50-54.

Production of Recombinant Collagen for Biomedical Devices. F. Ruggiero, H. Chanut, A. Fichard, May 2000, pp. 32-37.

The Industrial Production Costs of Recombinant Therapeutic Proteins Expressed in Transgenic Corn. D. Mison, J. Curling, May 2000, pp. 48-54.

Transgenic Protein Production. P. Rohricht, March 1999, pp. 46-49.

Transgenic Protein Production: Part 2, Process Economics. P. Rohricht, September 1999, pp. 52-54.

Transgenic Protein Production: Part 3, Nuclear Transfer Technology. P. Rohricht, D. Ayares, November 1999, pp. 56-60.

Transgenics Go Commercial. M. Young, W.B. Okita, July 1998, pp. 24-28.

Validation

A Guide to Determining Sample Sizes and Outlier Criteria in Analytical Investigations. J.D. Hofer, E.C. Rickard, May 2001, pp. 32-41, 68.

A Practical Guide to Executing Validation Protocols. G.S. Hodgson, April 1999, pp. 30-32.

A System Developer's Approach to Validation. C.L. Gent, March 2002, pp. 46-50, 72.

Business Benefits of Computer Systems Validation. M.J. Veverka, March 2002, pp. 52-54, 72.

Cell Bank Validation: Comparing Points to Consider and ICH Guidelines. M.S. Lao, January 1999, pp. 48-51.

Design and Validation of Isolator Systems for the Manufacturing and Testing of Health Care Products: Highlights from the New PDA Technical Report No. 34. R.E. Madsen, July 2001, pp. 30-32.

Designs for Bioassays with Plate Location Effects. B. Schlain et al., November 2001, pp. 40-44.

Detecting PEG-rHu MGDF in Rhesus Monkey Serum. D. Chen et al., April 2000, pp. 48-50.

Detection of Microbial Contamination in Cell Cultures Using a Laser Scanning System. A.O. Onadipe, April 2001, pp. 38-40.

Determining the Useful Lifetime of Chromatography Resins: Prospective Small-Scale Studies. R.M. O'Leary et al., September 2001, pp. 10-18.

Development of an In Situ Spectroscopic Method for Cleaning Validation Using Mid-IR Fiber-Optics. N.K. Mehta et al., May 2002, pp. 36-42, 71.

Documentation: It's Not Just Paper Work. D. Feuerhelm, G.S. Blank, August 2001, pp. 18-21, 64.

Effect of Heat Treatment on Four Viruses Inoculated into BSA and Bovine Transferrin Solution. Z.M. Plavsic, June 2000, pp. 54-56.

Elements of Downstream Bioprocess Validation. N.M. Lugo, June 1998, pp. 18-26.

Ensuring Successful Validation: The Logical Steps to Efficient Cleaning Procedures. G. Amer, P. Desmane, March 2001, pp. 26-32.

From R&D to Licensing: What to Do and When to Do it. G. Sofer, January 2001, pp. 18-27.

Implementing 21 CFR Part 11 in Analytical Laboratories: Part 3, Ensuring Data Integrity in Electronic Records. W. Winter, L. Huber, March 2000, pp. 45-49.

Implementing 21 CFR Part 11 in Analytical Laboratories: Part 5, The Importance of Instrument Control and Data Acquisition. W. Winter, L. Huber, September 2000, pp. 52-56.

Information Age Audits. J.F. Noferi, D.E. Worden, E.R. Arling, January 2002, pp. 35-39, 50.

Intentionally Degrading Protein Pharmaceuticals to Validate Stability-Indicating Analytical Methods. J. Yu, November 2000, pp. 46-50.

Master Planning and Validation: Part 1, Anatomy of a Validation Master Plan. J. Agalloco, March 2000, pp. 40-44, 70.

Master Planning and Validation: Part 2, System Definition. J. Agalloco, April 2000, pp. 34-38.

Meeting the Challenges of Enzyme Assay Validation. U. Patel, July 2000, pp. 48-52.

Multiuse Chromatography System: A Clean-in-

- Place Validation Case Study. P. A. Garipey, R.S. Moore, September 1998, pp. 32–36.
- Performance Qualification of Clean-in-Place Systems: Lessons from Experience in Multiproduct Biopharmaceutical Manufacturing. L. Hill, April 2000, pp. 24–29.
- Preparing for Team Biologics Inspections: Improving Your Chances of Success. R.F. Tetzlaff, August 1998, pp. 18–28.
- Process Hazard Analysis and Critical Control Point Identification. C. DeSain C. Sutton, October 2000, pp. 36–40.
- Process Validation: How Much to Do and When to Do It. A.S. Rathore et al., October 2002, pp. 18–28.
- Qualification of Network Components and Validation of Networked Systems. L. Huber, R. Budihandjo, October 2001, pp. 18–26, 46.
- Regulatory Requirements for Somatic Cell Therapy Products: Safety Concerns and Practical Solutions. M.S. Lao, March 2000, pp. 50–55.
- Resistance of Porcine Circovirus to Gamma Irradiation. Z.M. Plavsic, S. Bolin, April 2001, pp. 32–36.
- Retrovirus and Parvovirus Clearance from an Affinity Column Product Using Adsorptive Depth Filtration. B. Tipton et al., September 2002, pp. 43–50.
- Revisiting Validation: Continuing Concerns, New Challenges. G. Sofer, October 1999, pp. 26–30.
- Statistical Tools for Setting In-Process Acceptance Criteria. R.J. Seely, L. Munyakazi, J. Haury, October 2001, pp. 28–34.
- Statistics for Laboratory Method Comparison Studies. R.T. Magari, January 2002, pp. 28–32.
- The Evolving Role of Product Characterization During Development. J. Faulkner, June 2000, pp. 26–34.
- The FDA Regulatory Methods Validation Program for New and Abbreviated New Drug Applications. T. Layloff et al., January 2000, pp. 30–38.
- The Integration of Design, Construction, and Validation: Solving a Validation Challenge. J.N. Odum, November 1998, pp. 36–41.
- Tutorial: Establishing a Calibration Management Program. D.M. Evans, J. Erickson, May 1998, pp. 105–106.
- Tutorial: In Search of Standardized Definitions for Validation, Qualification, Verification, and Calibration. L. Huber, April 1999, pp. 56–58.
- Tutorial: Qualification of Quality Control Laboratory Equipment. T.J. Pritchett, January 1998, pp. 57–58.
- Tutorial: Qualifying High-Performance Liquid Chromatography/Mass Spectrometry Systems. W.P. Duncan, October 1999, pp. 65–66.
- Tutorial: The Importance of Time Variables in Temperature Studies. P. A. Hugunin, G. Straub, February 2000, pp. 73–74.
- Tutorial: Validation of HPLC Methods. L. Huber, March 1999, pp. 64–66.
- Validating a Refrigerator-Freezer. P. A. Cloud, November 1998, pp. 47–50.
- Validating Computer Systems for Clinical Trials, Part 1. G. Benghiat, A. Miller, January 1999, pp. 39–41.
- Validating Computer Systems for Clinical Trials, Part 2. G. Benghiat, A. Miller, March 1999, pp. 51–54.
- Validating Computerized Systems Developed Out of House. J. Gottfried, October 1998, pp. 40–43.
- Validating Critical Reagents Used in CGMP Analytical Testing. N. Ritter, M. Wiebe, May 2001, pp. 12–21.
- Validating the Sanitization of Chromatographic Resins: A Sample Case Study. M. Hiraoka-Sutow, C. Broughton, April 2001, pp. 26–30, 52.
- Validation of a Cation-Exchange Method to Test for Residual Amounts of a Cleaning and Sanitizing Solution on Pharmaceutical Process Equipment. M.J. Shifflet, M. Shapiro, January 2000, pp. 51–54, 64.
- Validation of a Chemiluminescent Hybridization Assay for Quantitative Determination of Host Cell DNA in Clarified Conditioned Medium. B. DiPaolo, X. Ji, K. Venkat, May 1999, pp. 38–48.
- Validation of Large-Scale Chromatographic Processes: Part 1, Case Study of Neuleze Capture on Macroprep High-S. T.N. Breece, E. Gilkerson, May 2002, pp. 16–20.
- Validation of Large-Scale Chromatographic Processes: Part 2, Results from the Case Study of Neuleze Capture on Macroprep High-S. T.N. Breece, E. Gilkerson, July 2002, pp. 35–42.
- Validation of Quantitative PCR Assays: Addressing Virus Contamination Concerns. A. Lovatt et al., March 2002, pp. 22–32.
- Viral Clearance Strategies for Biopharmaceutical Safety: Part 1, General Considerations. H. Aranha, January 2001, pp. 28–35.
- Viral Clearance Strategies for Biopharmaceutical Safety: Part 3, A Multifaceted Approach to Process Validation. H. Aranha, S. Forbes, May 2001, pp. 42–54, 90.
- Virus Inactivation in the 1990s — and into the 21st Century: Part 1, Skin, Bone, and Cells. G. Sofer, July 2002, pp. 18–24.
- Virus Inactivation in the 1990s — and into the 21st Century: Part 2, Red Blood Cells and Platelets. G. Sofer, August 2002, pp. 42–49.
- Virus Inactivation in the 1990s — and into the 21st Century: Part 3a, Plasma and Plasma Products (Heat and Solvent/Detergent Treatments). G. Sofer, September 2002, pp. 28–42.
- Virus Inactivation in the 1990s — and into the 21st Century: Part 3b, Plasma and Plasma Products (Treatments Other than Heat or Solvent/Detergent). G. Sofer, October 2002, pp. 42–49, 51.

Viral Inactivation

- Detecting and Removing Porcine Viruses to Prevent Contamination of Biopharmaceutical Raw Materials. B.J. Potts, W.J. Kivens, May 2000, pp. 26–31.
- Effect of Heat Treatment on Four Viruses Inoculated into BSA and Bovine Transferrin Solution. Z.M. Plavsic, June 2000, pp. 54–56.
- Evaluation of Two Bovine Cell Lines as Hosts for Detecting Several Common Bovine Viruses in Fetal Bovine Serum. Z.M. Plavsic, September 2000, pp. 48–51.
- Inactivation of Several Bovine Viruses in Fetal Bovine Serum Using pH Adjustments. Z.M. Plavsic et al., November 2000, pp. 34–38.
- Inactivation of Viruses and Mycoplasmas in Fetal Bovine Serum Using 56 °C Heat. D.J. Danner, J. Smith, M. Plavsic, June 1999, pp. 50–52.
- Purifying the Sendai Virus in One Step Using Ion-Exchange Chromatography. J. Eveleth et al., January 2000, pp. 40–43.
- Resistance of Porcine Circovirus to Gamma Irradiation. Z.M. Plavsic, S. Bolin, April 2001, pp. 32–36.
- Retrovirus and Parvovirus Clearance from an Affinity Column Product Using Adsorptive Depth Filtration. B. Tipton et al., September 2002, pp. 43–50.
- Some Methods for Contamination Testing of a Master Cell Bank. M. Aleman et al., June 2000, pp. 48–52.
- Validation of Quantitative PCR Assays: Addressing Virus Contamination Concerns. A. Lovatt et al., March 2002, pp. 22–32.
- Viral Clearance Strategies for Biopharmaceutical Safety: Part 1, General Considerations. H. Aranha, January 2001, pp. 28–35.
- Viral Clearance Strategies for Biopharmaceutical Safety: Part 2, Filtration for Viral Clearance. H. Aranha, February 2001, pp. 32–43.
- Viral Clearance Strategies for Biopharmaceutical Safety: Part 3, A Multifaceted Approach to Process Validation. H. Aranha, S. Forbes, May 2001, pp. 42–54, 90.
- Virus Inactivation in the 1990s — and into the 21st Century: Part 1, Skin, Bone, and Cells. G. Sofer, July 2002, pp. 18–24.
- Virus Inactivation in the 1990s — and into the 21st Century: Part 2, Red Blood Cells and Platelets. G. Sofer, August 2002, pp. 42–49.
- Virus Inactivation in the 1990s — and into the 21st Century: Part 3a, Plasma and Plasma Products (Heat and Solvent/Detergent Treatments). G. Sofer, September 2002, pp. 28–42.
- Virus Inactivation in the 1990s — and into the 21st Century: Part 3b, Plasma and Plasma Products (Treatments Other than Heat or Solvent/Detergent). G. Sofer, October 2002, pp. 42–49, 51.

Column: Business Matters

- 1999 Predictions Are Optimistic. G.S. Burrill, March 1999, pp. 20–23.
- Biotech at the End of the Century. G.S. Burrill, September 1999, pp. 56–58.
- Biotech Will Recover!, G.S. Burrill, October 2002, pp. 52–54.
- Biotech's First Quarter '99 Showed Mixed Results. G.S. Burrill, June 1999, pp. 34–38, 66.
- Eclipsed by Catastrophe. G.S. Burrill, November 2001, pp. 51–54, 58.
- Financing Picks Up. G.S. Burrill, September 2001, pp. 48–53.
- Is a Turnaround in Sight? G.S. Burrill, June 2002, pp. 76–82.
- Personalized Medicine or Blockbusterology? G.S. Burrill, April 2002, pp. 46–50.

Column: GMP Issues

- An Electronic Eye Opener. B. Immel, June 1999, pp. 60–63.
- Environmental Monitoring and Other Facts of Life. B. Immel, March 1998, pp. 46–49.
- Meeting Requirements of the European Union. B. Immel, January 1998, pp. 46–49.
- New Beginnings. B. Immel, January 1999, pp. 52–55.
- On Complying with 21 CFR Part 11. B.K. Immel, August 2000, pp. 59–61.
- Reflections in the Mirror: Part 1, Working with Contractors. B. Immel, October 1998, pp. 44–47.
- Reflections in the Mirror: Part 2, Working with Clients. B. Immel, November 1998, pp. 51–52.
- Step Up to the Responsibility of QA and QC. B.K. Immel, February 2000, pp. 58–60, 70.
- The Essence of Training, Part 1. B. Immel, May 1998, pp. 90–95, 100.
- The Essence of Training: Part 2, "The Play's the Thing". B. Immel, June 1998, pp. 62–67, 70.
- The Forgotten GLPs. B. Immel, April 1999, pp. 40–43.

Column: Inside Washington

- Accelerating Biotech Development and Approval. J. Wechsler, July 2000, pp. 24–28.
- Attack Mounts on Pharmaceutical Prices. J. Wechsler, September 2002, pp. 52–58.
- Biologics, CTDs, and BSE. J. Wechsler, May 2001, pp. 60–64.
- Biotech Manufacturing: Obstacle or Opportunity? J. Wechsler, March 2002, pp. 55–57, 60.
- Biotechnology Benefits from Antibioterrorism Funding. J. Wechsler, April 2002, pp. 52–58.
- Biotechnology in the Limelight. J. Wechsler, January 2000, pp. 20–24.

- Biotechnology in the Limelight: The Year Ahead. J. Wechsler, January 2002, pp. 44–45, 57.
- Challenges for the Genomics Era. J. Wechsler, April 2001, pp. 44–48.
- Changes at FDA and CBER Reflect New Priorities and Pressures. J. Wechsler, October 1999, pp. 20–24.
- Coping with Compliance Changes. J. Wechsler, July 1998, pp. 18–22.
- Costs and Controls Challenge Manufacturers. J. Wechsler, February 2002, pp. 52–56.
- Crisis and Costs Grip Biotech Industry. J. Wechsler, October 2001, pp. 38–40, 59.
- Emphasis on Enforcement. J. Wechsler, August 2000, pp. 22–25.
- Expensive Pipeline Therapies Under Attack. J. Wechsler, June 2000, pp. 20–24.
- FDA Adopts Electronic Systems. J. Wechsler, March 1998, pp. 12–16.
- FDA Faces "Modernization". J. Wechsler, January 1998, pp. 10–13.
- FDA Launches Major CGMP Review. J. Wechsler, October 2002, pp. 56–58.
- FDAMA Reshapes FDA. J. Wechsler, April 1999, pp. 12–16.
- Fees and Funding for Biotechnology. J. Wechsler, November 2000, pp. 22–26.
- Harmonization at Home and Abroad. J. Wechsler, May 1998, pp. 24–26, 43.
- Harmonizing Biologics and Drugs. J. Wechsler, October 1998, pp. 16–19.
- Is Team Biologics Working? J. Wechsler, February 2001, pp. 50–54.
- Major Changes Ahead for FDA. J. Wechsler, November 2002, pp. 50–54.
- Manufacturing to Meet Patient Demand. J. Wechsler, August 2001, pp. 36–40.
- Marketing Issues Raise Concerns for Biotech Manufacturers. J. Wechsler, January 1998, pp. 16–20.
- Marketing Issues Raise Concerns for Biotech Manufacturers. J. Wechsler, November 1998, pp. 16–20.
- Medicare, Prices, and Research. J. Wechsler, November 1999, pp. 22–26.
- Medication Errors Draw Congressional Scrutiny. J. Wechsler, March 2000, pp. 22–26.
- New Commissioner, New Challenges. J. Wechsler, September 1998, pp. 12–20.
- New FDA Commissioner Faces Major Challenges. J. Wechsler, January 1999, pp. 15–18.
- One Hundred Years of Biotech Regulation. J. Wechsler, July 2002, pp. 48–50, 58.
- Patents, Privacy, and Gene Research. J. Wechsler, May 2000, pp. 20–24.
- Politics and Policies. J. Wechsler, July 2001, pp. 46–50.
- Rescuing the "R" in CBER. J. Wechsler, April 1998, pp. 10–14.
- Research and Regulations. J. Wechsler, March 2001, pp. 48–52.

- Research Practices and Industry Prices Under Attack. J. Wechsler, October 2000, pp. 26–30.
- Risk and Regulation at FDA. J. Wechsler, June 2001, pp. 64–67.
- Safety, Bioterrorism, Research: Top White House Priorities. J. Wechsler, April 2000, pp. 20–23.
- Safety, Quality, and Resources. J. Wechsler, May 1999, pp. 10–16.
- Safety, Risk, and Biotechnology Regulation. J. Wechsler, June 2002, pp. 83–85.
- Stability at Home and Abroad. J. Wechsler, June 1999, pp. 14–22.
- The Year Ahead: Reform and Regulatory Challenges. J. Wechsler, January 2001, pp. 48–49, 61.
- User Fee Program Seeks to Spur Biotech Development. J. Wechsler, August 2002, pp. 51–53.
- USP Tackles Standards for Biologics. J. Wechsler, September 2000, pp. 30–35.
- Vaccine Shortages Put Spotlight on Production. J. Wechsler, May 2002, pp. 44–52.

Column: Managing Your Career

- 30 Ways to Court Lady Luck. D.G. Jensen, May 1998, pp. 96–97, 100.
- A Monster of a Slump. D.G. Jensen, April 2000, pp. 58–59.
- Anatomy of a Search. D.G. Jensen, April 1998, pp. 52–53.
- Become a People Magnet, Part 1. D.G. Jensen, November 1999, pp. 63–64.
- Become a People Magnet, Part 2. D.G. Jensen, January 2000, pp. 60–62.
- Dirty Tricks and Sneaky Business. D.G. Jensen, June 2000, pp. 65–66.
- Discussing Your Weaknesses. D.G. Jensen, April 2001, pp. 51–52.
- Getting Yourself Out There. D.G. Jensen, August 2000, pp. 69–70.
- How to Win at Dogs and Ponies. D.G. Jensen, September 1999, pp. 59–60.
- How's the Job Market? D.G. Jensen, September 2001, pp. 54–55.
- In Pursuit of a Goal. D.G. Jensen, March 2001, pp. 54–56.
- Is Your Career Ready for the Next Millennium? D.G. Jensen, June 1999, pp. 64–66.
- It's Quitting Time. D.G. Jensen, January 1998, pp. 50–51.
- Leadership Styles '99. D.G. Jensen, April 1999, pp. 44–45.
- Motivating Innovators. D.G. Jensen, January 2001, pp. 50–51.
- Not a Natural Born Leader? D.G. Jensen, July 2001, pp. 52–54.
- Outside Looking In. D.G. Jensen, November 2000, pp. 68–70.
- Quantum Leaders at Work. D.G. Jensen, October 1998, pp. 48, 56.
- Recruiter-Proof Your Organization. D.G. Jensen, October 2001, pp. 42–46.

Rejecting Pareto. D.G. Jensen, October 2000, pp. 78–80.

Revisiting the Resume. D.G. Jensen, July 2000, pp. 71–72.

Rules of the Road: (Previously) Unwritten Rules of Success for Bio Careers. D.G. Jensen, January 1999, pp. 56–57.

Tales from the Trenches. D.G. Jensen, October 1999, pp. 54–55.

The Agony and the Ecstasy of the Job Search. D.G. Jensen, March 2000, pp. 58–59.

The Cover Letter: Door Opener Par Excellence. D.G. Jensen, September 2000, pp. 70–71.

The Final Cut. D.G. Jensen, May 1999, pp. 65–66.

The Job Seeker's Moments of Truth. D.G. Jensen, September 1998, pp. 50–51.

Time and How We Waste It. D.G. Jensen, May 2001, pp. 66–68.

Twenty Minutes a Day to a New Job. D.G. Jensen, May 2000, pp. 62–63.

Underemployment: Following the Path of Least Resistance. D.G. Jensen, June 1998, pp. 68–69.

Want to Be Headhunted? Part 2: Four Ways to Get a Recruiter's Attention. D.G. Jensen, June 2001, pp. 68–69.

Want to Be Headhunted? D.G. Jensen, February 2001, pp. 56–58.

When Thoughts Become Things: Positive Thinking or Positive Focusing? D.G. Jensen, March 1999, pp. 61–62.

Who's In Charge? Five Keys to Your Career Destiny. D.G. Jensen, August 1999, pp. 50–51.

Winning the Good Battle. D.G. Jensen, November 1998, pp. 54, 63.

Your Career: Pearls or Pinecones? (Part 2). D.G. Jensen, March 1998, pp. 50–51.

Column: Outsourcing Outlook

Aligning Client and Contractor Objectives. L. Michalski, K.K. Glass, March 2001, pp. 58–62.

Applying the Theory of Constraints. L. Michalski, J. Miller, September 2000, pp. 24–28.

Audits Aren't Enough to Ensure Quality. L. Michalski, J. Miller, April 2001, pp. 54–58.

Balancing the Benefits of Outsourcing. J. Miller, K.K. Glass, January 2001, pp. 52–56.

Benchmarking for the Bottom Line. M. Levin-Epstein, J. Miller, March 2000, pp. 17–20.

Contract Laboratory Services 2000 Survey. M. Levin-Epstein, J. Miller, June 2000, pp. 14–18.

Don't Overlook Cultural Differences. L. Michalski, J. Miller, July 2000, pp. 14–18.

Effective Communication Equals Successful Project Management. L. Michalski, J. Miller, May 2000, pp. 14–18.

E-Procurement: Reverse Auctions and the Supplier's Perspective. E.P. Moser, J. Miller, June 2002, pp. 86–88.

E-Procurement: Successfully Using and Managing Reverse Auctions. E.P. Moser, J. Miller, May 2002, pp. 54–58, 72.

E-Sourcing: Internet Facilitates Flexible Collaboration. J. Miller, January 2002, pp. 46–49.

Giving Contractors a Quality Advantage. J. Miller, September 2001, pp. 56–59.

How to Engage in a Strategic Outsourcing Relationship. L. Blumberg, J. Miller, August 2002, pp. 54–57, 62.

How to Identify Vendor Risk. L. Michalski, J. Miller, October 2000, pp. 20–25.

If a Tree Fell in the Forest. J. Miller, September 2002, pp. 60–63.

Looking Back, Looking Ahead. J. Miller, February 2001, pp. 60–62.

Managing the Risks in Outsourcing. J. Miller, June 2001, pp. 70–72.

Minimizing Loss in a Risky Business. L. Michalski, J. Miller, January 2000, pp. 10–18.

Optimizing Cross-Organizational Team Performance and Management. D.S. Zuckerman, M.B. Higgins, July 2002, pp. 52–56.

Performing Due Diligence on Private CROs. L. Michalski, J. Miller, July 2001, pp. 56–58, 70.

Public CROs Craft New Strategies to Achieve Financial and Strategic Objectives. J. Miller, April 2002, pp. 60–62, 67.

Reaping the Benefits of E-Procurement. H.B. Hayes, J. Miller, February 2002, pp. 60–62, 64.

Relationship Management. J. Miller, October 2001, pp. 48, 60.

Restructuring of Big Pharma Could Lead to Big Opportunities for Contract Manufacturers. J. Miller, M. Levin-Epstein, November 1999, pp. 16–20.

Should Companies Be Hiring Chief Resource Officers? L. Michalski, J. Miller, April 2000, pp. 16–19.

Stakes Rise for Blown Batches. J. Miller, August 2001, pp. 42–43, 64.

Succession Planning. L. Michalski, J. Miller, August 2000, pp. 16–20.

Technical Innovations in Data Management. J. Miller, K.K. Glass, November 2000, pp. 16–20.

Technology Lessons from the E-Marketplace Shakeout. J. Miller, May 2001, pp. 70–74.

Toward More Strategic Outsourcing. L. Michalski, J. Miller, February 2000, pp. 17–20.

Truth in Outsourcing. W. Bierce, J. Miller, November 2001, pp. 55–58.

Using Earned-Value Analysis for Better Project Management. H.B. Hayes, J. Miller, March 2002, pp. 58–60, 69.

Will CROs Find Opportunity in a Reinvigorated European R&D Sector? J. Lowenbach, J. Miller, November 2002, pp. 56–62.

Column: Patent Law

Continuation Patent Applications. H.M. Eisenberg, January 2001, pp. 59–61.

Foreign Patent Applications. H.M. Eisenberg, May 2001, pp. 76–77.

Foreign Patent Applications: The Patent Cooperation Treaty. H.M. Eisenberg, July 2001, pp. 59–60.

Inventorship vs. Ownership. H.M. Eisenberg, July 2000, pp. 68–70.

Inventorship. H.M. Eisenberg, March 2000, pp. 56–57.

Maintaining Laboratory Notebooks. H.M. Eisenberg, September 2000, pp. 68–69.

Patent Filing Deadlines and Bars to Patentability. H.M. Eisenberg, February 2000, pp. 56–57.

Patent Infringement. H.M. Eisenberg, September 2001, pp. 60–61, 72.

Patentability Searching. H.M. Eisenberg, October 2000, pp. 74–76.

Provisional Patent Applications. H.M. Eisenberg, March 2001, pp. 66–68.

Reading a Patent: Part 1, the Cover Page. H.M. Eisenberg, September 1999, pp. 14–18.

Reading a Patent: Part 2, The Description and the Claims. H.M. Eisenberg, November 1999, pp. 61–62, 64.

Recent Changes in U.S. Patent Law. H.M. Eisenberg, May 2000, pp. 60–61.

Rule 56: Duty of Candor and Good Faith. H.M. Eisenberg, November 2000, pp. 64–65, 70.

Column: Regulatory Affairs

1998: The Year That Was. January 1999, pp. 20–25.

Gene Therapy: Birth to Adolescence. N.J. Chew, September 2000, pp. 36–40.

Global Drug Development: Singing from the Same Songbook. N.J. Chew, May 1999, pp. 18–26.

Harmonizing the Validation of Analytical Procedures. E. Wiechert, N.J. Chew, August 1999, pp. 18–24, 51.

ICH Now: Harmony at the End of the Century. N.J. Chew, June 1999, pp. 24–32.

ICH Regulatory Communications. J. Burley, N.J. Chew, September 1999, pp. 20–24, 60.

Reinventing FDA: Part 2, Overcoming the Paper Tiger. N.J. Chew, J. Morgan, C. Wantowski, January 1998, pp. 14–19.

Reinventing FDA: Part 3, Postapproval Changes. J. Morgan, N.J. Chew, April 1998, pp. 16–18, 56.

Reinventing FDA: Part 4, Gene, Cell, and Tissue Therapies. N.J. Chew, May 1998, pp. 45–51.

- Reinventing FDA: Part 5, Chemistry Manufacturing and Controls. J. Morgan, N. Chew, June 1998, pp. 12–16, 71.
- Right from the Start: Conducting Clinical Trials that Succeed. T. Seeger, N.J. Chew, October 1998, pp. 20–24.
- The Fast Track to Market. N.J. Chew, March 1999, pp. 14–18.
- Xenotransplantation: Science, Regulation, and Ethics. N.J. Chew, September 1998, pp. 22–26, 64.
- Harmonizing Validation Processes: Beyond Common Goals. R. Price, August 1999, pp. 14–16.
- The New Science of Investing. B.H. Rudolph, V. Aslam, September 2000, pp. 20–22.

Column: Your Vested Interests

- Buy! Sell! Hold! B.H. Rudolph, V. Aslam, January 2001, pp. 62–64.
- Gene Therapy: Are You a Believer? B.H. Rudolph, V. Aslam, August 2001, pp. 44–45.
- Gorillas in Our Midst. B.H. Rudolph, August 2002, pp. 58.
- Image Is Everything. B.H. Rudolph, V. Aslam, October 2000, pp. 68–72.
- Is the Sky Really Falling? B.H. Rudolph, V. Aslam, May 2001, pp. 78–79.
- Other People's Money. B.H. Rudolph, V. Aslam, November 2000, pp. 62–63.
- Science in the Mannerist Style. B.H. Rudolph, V. Aslam, February 2001, pp. 68–70.
- Sector Spotlight: Molecular Evolution Companies. B.H. Rudolph, June 2001, pp. 73, 75.
- The Joys of Voodoo. B.H. Rudolph, V. Aslam, April 2001, pp. 59–60.
- The Not-So-Sure Thing. B.H. Rudolph, May 2002, pp. 60.
- The War of the West. B.H. Rudolph, V. Aslam, January 2002, pp. 51–53.

Department: Analytical Advances

- A Novel Enzyme-Linked Immunosorbent Assay for Studying DNA-Transcription Factor Interactions. L.B. English, January 2002, pp. 63, 64.
- Affinity Chromatography is Vital to Protein Research and Development. J.M. Curling, October 2001, pp. 51–52.
- Automated Dynamic and Static Light-Scattering Applications of the DynaPro Molecular Sizing Instrument. J. Jones, K.W. Mattison, August 2001, pp. 56–57.
- Calibration Management of Outsourced Calibrations. J. Erickson, February 2002, pp. 63–64.
- Chemical Management: A Practical Guide. M. Wysong, May 2002, pp. 75, 78.
- Controlled Clean Environment Enclosures: A Cost-Effective Alternative to Cleanrooms. R. Matthews, September 2002, pp. 64.

- GMPs and Pharmaceutical Labeling. D. Luedke, October 2002, pp. 60.
- High-Throughput Purification Systems for Oligonucleotides Improves Synthetic Gene Production. D. Pippen, April 2002, pp. 79–80.
- Lab-on-a-Chip Technology: Applications for the Life Sciences. M. Kuschel, August 2001, pp. 50–52.
- Mapping Proteins: The 2-D Electrophoresis Issue. K. McAloon, August 2002, pp. 63.
- Paperless or Less Paper? Weighing the Options. M.E. Goffredo, April 2002, pp. 78, 80.
- Protein Purification Using Ion-Exchange Membrane Spin Columns. M. Brownleader, January 2002, pp. 62, 64.
- Rapid Material Identification and Characterization. B. Davies, October 2001, pp. 52.
- Strategies in Clarifying Mammalian Cultures. C. Lambalot, May 2002, pp. 74.
- The Platform Approach to Clinical Data Management. D. Goodermote, August 2001, pp. 54.
- The Protein I.D. Autobahn - Automated Nanoelectrospray Mass Spectrometry. G. Schultz, November 2002, pp. 67–68.
- Using Image Informatics: Focusing Proteomics. S. Mattingly, May 2002, pp. 76.
- When an Industry Requires Multiterabyte Protection. R. Levine, July 2002, pp. 65.

Department: Guest Editorial

- Back to the Beginning. S. Schuber, November 2002, pp. 82.
- Quality Agreements with Contract Laboratories (Creating Documents that Meet GMPs and Make Good Business Sense). R. Blasini, August 2002, pp. 66.
- Revolutionizing Biologics Regulation. J. Wechsler, October 2002, pp. 66.
- Security in the Corporate Homeland. J.F. Noferi, September 2002, pp. 74.
- Supreme Court Rules on Festo. E.R. Ergenzinger Jr. W.M. Spruill, July 2002, pp. 66.
- The Protein Production Challenge. R. Andersson, R. Mynahan, April 2002, pp. 82.
- Validation Bingo. J.E. McIntire, May 2002, pp. 82.
- Warning Letters: A Symptom? S.S. Kuwahara, March 2002, pp. 74.

Department: Travel Notes

- Asilomar 2000: Symposium on Science, Ethics, and Society. C. Scott, March 2000, pp. 10–14.
- Biotechnology for Professionals. L.D. McLeod, March 2001, pp. 8.
- Biotechnology in Europe: Two Case Studies. C. Scott, April 2000, pp. 12–15.
- Michigan: It isn't Just for Automakers Anymore. L.D. McLeod, July 2002, pp. 8–10.
- Spokane, WA. L. McLeod, C. Scott, November 2000, pp. 8–10.
- Travel Notes: Snapshots of the Biopharmaceutical Industry in Baden-Württemberg. S.A. Montgomery, May 1998, pp. 22–23.
- Yes, Virginia, There is Biotech in the Commonwealth. L.D. McLeod, May 2002, pp. 12–14.

Department: Viewpoint

- A Marketing Solution for Emerging Biotechnology Companies. L.G. Lange, July 2000, pp. 20–21.
- Addressing the New Bottleneck. C. Scott, July 2001, pp. 14–15.
- Electronic Submissions: Faster Assembly and Review. S. Galle, January 2001, pp. 12–16.
- Sound Venture Capital Practices Come to Biotech. C.B. Feldman, August 2001, pp. 8–9.
- United Kingdom Highlights Biomanufacturing Capabilities. L. Magee, June 2002, pp. 12–16.
- Viewpoint: BioRegion - Using a Virtual Enterprise to Foster a Regional Biotech Industry. U. Jensen, May 1998, pp. 20–21.
- Viewpoint: BIOTechnopolitics: An Entrepreneur's Political Agenda. C.B. Feldbaum, June 1998, pp. 8–11.
- Viewpoint: Y2K Bug - A Millenium Debacle. K.P. Evans, B. Gibson, July 1998, pp. 14–17, 50. **BPI**